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1. Introduction 
 
1.1 Factor VIII: Function in blood coagulation 
 
To maintain the integrity of the vascular system which is critical to all higher organisms with 
closed circulatory systems, a complex, highly regulated system has evolved, consisting of 
extensive interactions between the endothelial cell lining of the blood vessels, the blood 
platelet, and an intricate cascade of plasma proteins (Davie et al., 1991; Flier and Underhill, 
1992; Broze, 1992; Colman et al., 1994 and Schafer, 1994). 
 
The coagulation cascade was one of the first biologic systems associated with human diseases 
to be studied in detail at the biochemical level (Ratnoff, 1991). It is an ordered cascade 
consisting of a plasma protease activating an inactive zymogene target to an active protease 
form, which subsequently acts on the next step in the cascade (Fig. 1). It is traditionally 
divided into the „intrinsic“ and „extrinsic“ pathways, but the biologic significance of this 
distinction has been recently questioned. The extrinsic pathway is now viewed as the major 
mechanism of coagulation under most circumstances, while the intrinsic pathway boost the 
coagulation. 
 
Coagulation begins almost instantly after an injury to the blood vessel has damaged the 
endothelium lining the vessel. Exposure of the blood to proteins such as tissue factor initiates 
changes to blood platelets. Platelets immediately form a plug at the site of injury; this is called 
primary hemostasis. Secondary hemostasis occurs simultaneously (Fig. 1): The sequential 
activation of plasma proteases in the intrinsic pathway of coagulation leading to the localized 
generation of thrombin, which then converts the fibrinogen to cross-linked fibrin polymers 
that strengthen the platelet plug (Furie B and Furie BC, 2005). FVIII is proteolytically 
activated by activated factor X (FXa) and thrombin. FVIII has no enzymatic activity of its 
own, but once activated, it acts as a cofactor to increase the maximal velocity of FX activation 
by activated factor IX (FIXa) in an order of 10.000 in the presence of negatively charged 
phospholipids and calcium (Kaufman 1992). In the next step, FXa acts in the presence of 
activated factor V (FVa), negatively charged phospholipids, and calcium to activate 
prothrombin to thrombin. Thrombin then enhances fibrin production and subsequently 
activated factor XIII (XIIIa) leads to the cross-linking of fibrin monomers. 
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Figure 1: The coagulation cascade. The intrinsic cascade (which has less in vivo significance in normal 
physiological circumstances than the extrinsic cascade) is initiated when blood and exposed negatively charged 
surfaces comes in contact to each other. The extrinsic pathway is initiated upon vascular injury which leads to 
exposure of tissue factor, TF (also identified as factor III), a subendothelial cell-surface glycoprotein that binds 
on phospholipids. The green dotted arrow represents a point of crossover between the extrinsic and intrinsic 
pathways. The two pathways converge at the activation of factor X to Xa. Active factor Xa hydrolyzes and 
activates prothrombin to thrombin. Beside this function, Factor Xa has a role in the further activation of factor 
VII to VIIa as depicted by the green arrow. The role of thrombin is to convert fribrinogen to fibrin and to 
activate factor XIII to XIIIa. (also termed transglutaminase). However, thrombin can also activate factors XI, 
VIII and V furthering the cascade. In the last step of coagulation, factor XIIIa cross-links fibrin polymers 
solidifying the clot. HMWK = high molecular weight kininogen. PK = prekallikrein. PL = phospholipid. 
 
 
Coagulation factor VIII (FVIII) is one of the key components of blood coagulation cascade 
(Mann 1999). It circulates in the bloodstream as a complex with von Willebrand factor 
(vWF), which protects and stabilizes FVIII (Saenko et al., 1999). Deficiency of FVIII activity 
leads to hemophilia A, a congenital bleeding tendency of variable severity that is caused by 
distinct FVIII gene mutations (Kemball-Cook et al., 1998). 
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1.2 Structure, biosynthesis and life cycle of factor VIII 
 
1.2.1 Factor VIII gene 
 
The FVIII gene has been localized to the distal Giemsa staining band positioned on the long 
arm of the X chromosome, Xq28 (Poustka et al., 1991; Freije and Schlessinger 1992). It is 
oriented with its 5’ untranslated region toward the telomere and thus it is transcribed toward 
the centromere. It spans over 180 kb, and -as such- is one of the largest genes known. The 
FVIII gene (Fig. 2) comprises 26 exons, which encode for a polypeptide chain of 2351 amino 
acids. This includes a signal peptide of 19 amino acids and a mature protein of 2332 amino 
acids (Wood et al., 1984; Vehar et al., 1984 and Toole et al., 1984). 
 
The coding sequences (26 exons) range from 69 to 262 bp except for exon 26 and exon 14. 
While exon 26 is nearly 2 kb and primarily contains 3’ untranslated sequence, exon 14 is the 
largest exon (3.1 kb). The FVIII cDNA and mRNAs are approximately 9kb (Thompson 
2003). 
 
Introns vary from 0.2 kb for intron 17 to 32 kb for intron 22. Within intron 22, there are two 
distinct non-FVIII gene elements controlled by a bidirectional promoter (Levinson et al., 
1990). The first, is a FVIII-associated A gene (F8A), a single exon transcribed in the opposite 
direction. Homologous recombination between the F8A gene and one of two almost identical 
copies that are localized telomeric of the FVIII gene leads to FVIII gene interruption and 
accounts for nearly half of the families with severe hemophilia A (Kemball-Cook et al., 
1998). The second gene, F8B, represents an initial new first exon that is transcribed in the 
same direction as FVIII and includes FVIII’s exons 23 to 26 (Levinson et al., 1992). The first 
intron of the FVIII gene contains a 1-kb sequence, int1h-1, that is repeated in opposite 
direction outside of the 5’ FVIII gene in a distance of 140 kb. (Bagnall et al., 2002). These 
sequences provide additional sites of homologous recombination events, accounting for 
approximately 5% of families with severe hemophilia A. 
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Figure 2: Factor VIII gene. The 26 exons (e) and their intervening sequences (i) are shown. Exon 14 is the 
largest follwed by exon 26, which is composed primarily of 3’ untranslated sequences (ut). Within the large 
intron 22 are the A and B genes that share a bidirectional promotor (◊ and arrows). (Thompson 2003). 
 
 
1.2.2 Biosynthesis and processing of factor VIII 
 
Factor VIII mRNA has been demonstrated in a variety of tissues, including spleen, lymph 
nodes, liver, and kidney (Wion et al., 1985; Levinson et al., 1992; Elder et al., 1993). 
However, the liver most likely provides the primary source of FVIII (Lenting et al., 1998). 
Studies on factor VIII biosynthesis and secretion have been limited by the lack of human cell 
lines that properly express significant amounts of FVIII. The best evidence for the 
intracellular synthetic pathways comes from nonhuman, mammalian cell lines (like COS and 
CHO cell lines) transfected with FVIII cDNA. These studies showed that, in general, FVIII is 
poorly expressed (Thompson 2003). Low expression is associated with a low level of steady- 
state mRNA (Kaufman et al., 1989) and inefficient secretion (Dorner et al., 1987). 
 
FVIII is synthesized as a 2351-amino-acid single chain precursor from which a 19-amino-acid 
signal peptide is cleaved upon translocation into the lumen of the endoplasmic reticulum 
(ER). In the ER, high mannose oligosaccharides are added to multiple asparagine (Asn) 
residues within the FVIII molecule, a process known as glycosylation (Kaufman 1992). 
Within the ER, factor VIII appears to interact with a number of chaperone proteins, including 
calreticulin, calnexin, and the Immunoglobulin-binding protein (BiP) (Dorner et al., 1989; 
Marquette et al., 1995; Swaroop et al., 1997; Pipe et al., 1998). Due to the interaction with 
these chaperone proteins, a significant proportion of the FVIII molecules are retained within 
the ER, thereby limiting the transport of FVIII to the Golgi apparatus (Lenting et al., 1998). 
Release from Bip is energy dependent and necessary before FVIII can be transported to the 
Golgi apparatus, basically by another chaperone protein, the endoplasmatic reticulum-Golgi 
intermediate compartment-53 (ERGIC-53). The interaction with ERGIC-53 is mannose 
dependent and primarily involves Asn-linked oligosaccharides within the B domain 
(Moussalli et al., 1999; Cunningham et al., 2001; Pipe 2009). Within the Golgi, Asn-linked 
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carbohydrates are modified, O-linked sugars are added to specific Ser and Thr residues within 
the B domain, disulfide bonding and protein folding occur, and six Tyr residues (within the 
three acidic peptide sequences) are sulfated (Fig. 3) (Thompson 2003). Sulfation of tyrosine 
residues increases the procoagulant activity of FVIII and is required for high affinity 
interaction with vWF (Pittman et al., 1992; Leyte et al., 1991). In addition, FVIII is among 
the many proteins that undergo intracelullar proteolysis (Kaufman et al., 1988, van de Ven 
WJM et al., 1990, Hutton 1990). FVIII is cleaved after residues 1313 and 1648 within the B 
domain to generate a 200 kDa amino-terminal-derived heavy chain (A1-a1-A2-a2-B) and an 
80 kDa carboxy-terminal-derived light chain (a3-A3-C1-C2), giving rise to the heterodimeric 
molecule that circulates in plasma (Kaufman 1992) (Fig. 4 A and B). 
 
1.2.3 Factor VIII protein structure 
 
Analysis of the deduced primary structure determined from the cloned FVIII cDNA showed 
the presence of a discrete domain structure: A1-a1-A2-a2-B-a3-A3-C1-C2 (Wood et al., 
1984; Vehar et al., 1984; Toole et al., 1984 and Fay 2006) (Fig. 3). The A domains of FVIII 
occur twice in the heavy and once in the light chain and have 30% homology to each other. 
The C domains occur twice in the carboxy terminus of the FVIII light chain and exhibit 
homology to proteins that bind glycoconjugates and negatively charged phospholipids (Poole 
et al., 1981; Stubbs et al., 1990). The B domain, encoded by a single large exon of 3.1 kb 
(Exon 14), has no known homology to other proteins, and contains 18 of the 25 potential 
asparagine (N)-linked glycosylation sites within FVIII (Kaufman 1992; Pipe 2009). The A 
domains are bordered by short spacers (a1, a2, and a3) that contain clusters of Asp and Glu 
residues, the so-called acidic regions (Lenting et al., 1998). 
 
The three homologous A domains bind Ca2+ and are essential for catalytic cofactor activity 
(Lollar et al., 1993). The short acidic sequences between A1 and A2 and at the A2-B and B- 
A3 junctions contain sulfated Tyr residues (Pittmann et al., 1992). Most of the large, central B 
domain can be deleted without losing FVIII activity (Pittman et al., 1993; Eaton et al., 1986). 
The acidic sequence connecting B with A3 (Glu1649-Arg1689) contains a major vWF-binding 
site (Foster et al., 1988) that requires sulfation of Tyr1680 for vWF binding (Leyte et al., 1991). 
C1 and C2 domains have homologies with FV and a class of lectins (Kane and Davie, 1988). 
These carboxy-terminal domains contribute to vWF, FIX, FX binding, and also help FVIIIa to 
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bind to phospholipids (Thompson 2003). In addition, thrombin and FXa appear to bind to a 
site on the surface of C2 domain (Nogami et al., 2000 and 1999). 
 
 
Figure 3: The factor VIII protein. Mature factor VIII consists of 2332 amino acids, which are arranged in a 
discrete domain structure: A1 (residues 1-336), A2 (373-710), B (741-1648), A3 (1690-2019), C1 (2020-2172) 
and C2 (2173-2332). The A domains are bordered by acidic regions a1 (337-372), a2 (711-740) and a3 (1649- 
1689) (Lenting et al., 1998). 
 
 
1.2.4 Factor VIII in circulation: 
 
FVIII circulates at 0.2 ug/ml in plasma as a heterodimer that is processed from a single 
polypeptide upon secretion from the cell (Kaufman 1992) (Fig. 4 B). It circulates in complex 
with vWF, an association that not only stabilizes and protects FVIII, but also helps to localize 
FVIII to sites of vessel wall damage (Fay and Jenkins 2005; Lenting et al., 2010). The half- 
life of FVIII is much shorter than that of vWF. About 95% of FVIII is bound at any time to 
vWF in vivo with a molar ratio of about 1:50 (Vlot et al., 1995). 
 
Recent evidence suggests that the extrinsic pathway may be the most significant physiologic 
initiator of FVIIIa generation. FVII initiates the FVIII activation and FXa and thrombin 
generation provide positive feedback to amplify FVIII activation (Kaufman 1992). Activation 
of FVIII proceeds by limited proteolysis catalyzed by thrombin or factor Xa, with the former 
likely representing the physiologic activator (Pieters et al., 1989; Fay 2004). Thrombin binds 
to the sulfonated acidic peptides a1, a2, and a3 and cleaves peptide bonds after Arg372, Arg740, 
Arg1689, respectively (Thompson 2003) (Fig. 4 B and C). In detail: cleavage within the heavy 
chain after Arg740 generates a 90-kDa polypeptide (A1-A2), which is subsequently cleaved 
after Arg372 to generate polypeptides of 50 (A1) and 43 (A2) kDa. Cleavage of the FVIII 
heavy chain at Arg372 is essential to expose a factor IXa-interactive site (Fay et al., 2001), 
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generation provide positive feedback to amplify FVIII activation (Kaufman 1992). Activation 
of FVIII proceeds by limited proteolysis catalyzed by thrombin or factor Xa, with the former 
likely representing the physiologic activator (Pieters et al., 1989; Fay 2004). Thrombin binds 
to the sulfonated acidic peptides a1, a2, and a3 and cleaves peptide bonds after Arg372, Arg740, 
Arg1689, respectively (Thompson 2003) (Fig. 4 B and C). In detail: cleavage within the heavy 
chain after Arg740 generates a 90-kDa polypeptide (A1-A2), which is subsequently cleaved 
after Arg372 to generate polypeptides of 50 (A1) and 43 (A2) kDa. Cleavage of the FVIII 
heavy chain at Arg372 is essential to expose a factor IXa-interactive site (Fay et al., 2001), 
whereas cleavage at Arg740 removes the B domain or its fragments from A2 subunit (Fay and 
Jenkins 2005).  Concomitantly, the 80 kDa light chain (A3-C1-C2) is cleaved after Arg1689 to 
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whereas cleavage at Arg740 removes the B domain or its fragments from A2 subunit (Fay and 
Jenkins 2005). Concomitantly, the 80 kDa light chain (A3-C1-C2) is cleaved after Arg1689 to 
generate a 73-kDa polypeptide (Eaton et al., 1986). Furthermore, cleavage at 1689 releases 
FVIII from vWF, relieving the vWF inhibition of FVIII-phospholipid interaction (Pittman and 
Kaufman, 1989; Hill-Eubanks et al., 1989) and permitting the interaction of FVIII with 
platelets where it interact with FIXa and FX. 
 
Inactivation of the cofactor comprises two distinct pathways: spontaneous dissociation and 
proteolytic degradation. Activated FVIII may be inactivated through spontaneous dissociation 
of the A2-domain (43-kDa subunit) (Fig. 4 D) from the rest of the molecule. The association 
of A2 subunit with the A1/A3–C1–C2 dimer is a weak interaction by affinity forces and 
dissociation of A2 represents the primary mechanism for the observed lability of FVIIIa and 
the self-dampening of factor X activity (Eaton et al., 1986). FVIIIa is proteolytically degraded 
within the heavy chain by various enzymes; such as factor IXa, factor Xa and activated 
protein C (APC) (Koedam et al., 1990; Rick et al., 1990; O’Brien et al., 1992). APC cleaves 
FVIIIa after residues 336 and 562 and FXa cleaves it after residues 336 and 36 (Eaton et al., 
1986; Fay et al., 1991) (Fig. 4). Cleavage at position 336 in FVIIIa releases a1, the acidic 
sequence that interconnects the A1 and the A2 domain. Because of this release, the A2 
domain dissociates more rapidly from the factor VIIIa heterotrimer (Fay et al., 1993). This 
acidic spacer has been proposed to comprise a binding site for the substrate factor X (Regan et 
al., 1996; Lapan and Fay 1997), indicating that release of this site results in impaired 
substrate binding. Thus, cleavage at Arg336 affects both intramolecular (A2 domain 
dissociation) and intermolecular (FVIII-FX) interactions (Lenting et al., 1998). Inactivation 
most closely correlates with cleavage at residue 562. Arg562, which is part of the A2 domain 
sequence that comprises a factor IXa interactive site, is exclusively cleaved by APC (Fay et 
al., 1991). It seems conceivable that loss of cofactor activity due to cleavage at this site reflect 
the loss of the ability to interact with factor IXa (Lenting et al., 1998). The activation of 
protein C by thrombin is regulated by thrombomodulin on the endothelial cell surface (Esmon 
1989). 
 
FVIII is removed from the blood circulation at least in part by binding to low-density 
lipoprotein-related receptor protein (LRP) on the surface of hepatic endothelial cells 
(Schwartz et al., 2000). This binding is facilitated by cell surface heparans (Sarafanov et al., 
2001). 
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Figure 4: Scheme of proteolytic conversions of factor VIII in the course of processing, activation and 
inactivation. HC: heavy chain; LC: light chain; APC, activated protein C; FXa, activated factor X. (modified of 
Khrenov et al., 2006). 
 
 
1.3 Hemophilia A 
 
1.3.1 Phenotype 
 
Hemophilia A (OMIM 306700) is the most common inherited severe bleeding disorder. Its X- 
linked pattern of inheritance was first recognized by Jewish scholars in the second century 
AD (Ingram, 1976; Ratnoff, 1991). Hemophilia A is a heterogeneous disorder resulting from 
defects in the FVIII gene that lead to a reduction in the circulating levels of functional FVIII. 
The reduction in activity can be due to a decreased amount of FVIII protein, the presence of a 
functionally abnormal protein, or a combination of both. In patients with hemophilia, clot 
formation is delayed because thrombin generation is markedly decreased. The clot that is 
formed is friable and easily dislodged, thus resulting in excessive bleeding and poor wound 
healing (Christiansen et al., 2010; Williams Hematology, 5th edition, 1995). 
 
The clinical manifestations of hemophilia A vary considerably and range from severe 
bleedings already visible shortly after birth until very mild phenotypes that are only diagnosed 
very late in life and during operations (Jones and Ratnoff, 1991; Hoyer, 1994; Furie et al., 
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1994). The severity of the disease can be predicted quite accurately from the level of residual 
FVIII activity. Patients with very low or no FVIII activity (<1%) are affected with severe 
hemophilia A, whereas those with FVIII levels of 1-5% have moderate and those with 5-25% 
FVIII activity have mild hemophilia. FVIII levels above 25% are generally associated with a 
normal phenotype. 
 
Classic (severe) hemophilia is characterized by excessive bleeding into various parts of the 
body. Soft tissue hematomas and hemarthroses are highly characteristic of the disease. 
Severely affected patients with hemophilia may experience bleeding without known trauma. 
Hemarthroses become frequent at about the time the patient begins to walk. Without effective 
treatment, recurrent hemarthroses, resulting in chronic hemophilic arthropathy, occur by 
young adulthood and are highly characteristic of the severe form of the disorder. Moderately 
affected patients with hemophilia have occasional hematomas and hemarthroses, usually, but 
not always, associated with known trauma. Although hemarthroses occur in moderately 
affected patients, hemarthropathy is less disabling than that occurring in severely affected 
patients. Mildly affected patients have infrequent bleeding episodes, and the disease may go 
undiagnosed for years, only to be discovered because of excessive hemorrhage 
postoperatively, following trauma, or after the toss and tumble of contact sports. Female 
carriers of the disease have roughly 50% FVIII activity and experience no bleeding difficulty, 
even with surgical procedures (Williams Hematology, 5th edition, 1995). 
 
A broad spectrum of genetic defects within the FVIII gene has been identified, resulting in a 
range of hemophilia phenotypes determined by the amount of residual FVIII activity 
(Tuddenham et al., 1994; Hoyer, 1994; Antonarakis et al., 1995a). The frequency of 
hemophilia A in the population is estimated to be approximately 1:10 000-1:5000 of all born 
males (Soucie et al., 1998). As predicted by the Haldane hypothesis, about one-third of cases 
appear to be new mutations. A large number of hemophiliacs have been studied at the DNA 
level (Tuddenham et al., 1994) and a regularly update database of known mutations can be 
assessed at: http://hadb.org.uk/ 
 
1.3.2 Assessment 
 
Patients with severe hemophilia A characteristically have a prolonged activated partial 
thrompoplastin time (APTT) (see section 2.4.2.1) and a prolonged whole blood clotting time 
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Different combinations of APTT reagents and instrumentation exhibit widely varying 
sensitivities to FVIII levels. Functional FVIII activity (FVIII: C) is measured by clotting 
assays. FVIII protein is measured by immunologic assays of FVIII antigen (FVIII: Ag), which 
will detect both normal and abnormal FVIII molecules. If the FVIII antigen level is normal, 
but the clotting activity is reduced, the patient has a dysfunctional FVIII molecule. FVIII 
activity is expressed as percent of normal (normal: 100% FVIII: C) or as units per milliliter of 
plasma (normal range: 1U/ml). One unit FVIII per ml is 100 percent of normal (William’s 
Hematology, 5th edition, 1995). 
 
1.3.3 Current therapy and side effects 
 
Treatment of hemophilia A rests on replacement of the deficient FVIII activity. Hemophilia A 
was initially treated with unpurified plasma, which contains 1 U/mL of FVIII activity. The 
cryoprecipitate fraction of the plasma was subsequently shown to be enriched for FVIII 
activity, thus permitting administration of smaller volume. Over the past three decades, highly 
purified FVIII concentrates have become the main therapy for hemophilia A. Standard 
commercial concentrates are prepared from plasma that has been generally pooled from 2000- 
200,000 donors. Unfortunately, the purification process used until the mid-1980s failed to 
inactivate common viral contaminants, including hepatitis B and C, cytomegalovirus (CMV) 
and HIV. As a result, all these infections were nearly uniform among patients heavily treated 
during the late 1970s and early 1980s. To prevent possible viral infections, purification 
methods were developed to inactivate all these viruses by detergent or heat treatment. 
Monoclonal antibody purification procedures further improved the quality of these products. 
As a result, all currently available FVIII concentrates are thought to be free of viral hazard 
(Brettler and Levine, 1989; Hoyer 1994; Furie et al., 1994). 
 
With the advent of recombinant biotechnology, cloning of the FVIII gene led to the 
development and production of the first generation of commercially available recombinant 
FVIII (rFVIII) products, heralding a new era of viral safety in the treatment of hemophilia A 
(Tuddenham 2003). 
 
Newly diagnosed and previously untreated patients are generally managed with recombinant 
FVIII or highly purified plasma-products, whereas most clinicians prefer the former. Many 
hemophiliacs are followed in comprehensive clinics, where they receive multidisciplinary 
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care. A dose of FVIII of approximately 50 U/kg will generally raise the level from 0% to 
100%. The half-life of FVIII is approximately eight hours, requiring repeated doses in case of 
severe hemophilia (2-3 times a week) or treatment by continuous infusion. Therapy is 
monitored by following the FVIII activity level. A FVIII level of 50% or more should achieve 
normal homeostasis, even under extreme conditions. 
 
Approximately 10-20% of patients develop inhibitor antibodies to FVIII that dramatically 
complicate therapy. These antibodies can reach extremely high titers, and infusions of 
sufficient FVIII to overwhelm the inhibitor may often be impractical. A variety of strategies 
have been used to treat these inhibitors, including immunosuppression and various regimens 
to induce tolerance (Hoyer, 1994; Furie et al., 1994). The most commonly used protocol to 
eradicate inhibitors is still the ‘Bonn protocol’ (Brackmann et al., 1996). 
 
1.4 Recombinant factor VIII molecules 
 
The first generation of rFVIII molecules was produced by insertion of a full-sequence human 
FVIII cDNA into expression vectors, yielding what is typically referred to as ‘full-length’ 
rFVIII (FL-rFVIII), which is biochemically and functionally similar to plasma-derived FVIII 
(pdFVIII) (Eaton et al., 1987). In 1992, the company Baxter in conjunction with the Genetics 
Institute introduced the world’s first genetically engineered factor VIII under the name of 
‘Recombinate’. Then in February 1993, Genetech produced second recombinant factor VIII 
product named ‘Kogenate’. The ‘first generation’ of recombinant products used animal 
products in the culture medium and contained human albumin added as a stabilizer. 
 
As the B-domain is not required for FVIII procoagulant activity (Andersson et al., 1986), 
bioengineering of the FVIII molecule by removing the B-domain was found to dramatically 
improve the yield of rFVIII (Dorner et al., 1987), enhancing expression of rFVIII as much as 
20-fold (Pittman et al., 1993). The removal of the B-domain coding sequence brought several 
advantages compared to the full-length molecule. The shorter cDNA led to a large increase of 
FVIII mRNA amounts (Pittman et al., 1993; Pipe et al., 1998; Pittman et al., 1994) that 
resulted in an improved production of a 170 kDa FVIII protein, secreted as an association of 
heavy chain (A1-A2; 90 kDa) and light chain (A3-C1-C2; 80 kDa) (Pittman et al., 1993). 
Such advantages rendered the BDD-FVIII more attractive for producing recombinant FVIII 
compared to the FL-rFVIII (Sandberg et al., 2001). In addition, the limited size of the cDNA 
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construct allowed its insertion in most viral vectors that were used for gene therapy studies 
(Chao et al., 2000; Connelly et al., 1996; Gnatenko et al., 1999; VandenDriessche et al., 
1999). 
 
Recombinant FVIII with the B-domain deleted (BDD-rFVIII) (moroctocog alfa; ReFacto 
[Wyeth]) was developed with an albumin-free formulation to decrease the risk of pathogen 
transmission (second-generation rFVIII products). Since the licensure of ReFacto, the 
portfolio of FVIII concentrates has expanded to include additional FL-rFVIII preparations, 
Kogenate FS (Kogenate Bayer in the USA) [octocog alfa (Bayer)] and Advate (octocog 
alfa [Baxter]). Both have been produced using animal-derived materials in the culture 
medium, but instead of albumin, they used sucrose or other non-human derived material as a 
stabilizer. ‘Third generation’ products have no human or animal protein during the production 
process. Advate and newly ReFacto AF made by Wyeth are examples (Franchini and Lippi, 
2010). 
 
While BDD-rFVIII is effectively used in the treatment of haemophilia A patients, recent 
experimental and clinical studies revealed a number of issues related to its equivalency to 
plasma-derived-FVIII (Gruppo et al., 2003; Lollar 2003). In particular, it was shown that the 
activity of BDD-rFVIII determined by one-stage clotting assay is up to 50% lower than that 
determined by chromogenic assay, thus complicating determination of BDD-rFVIII activity in 
hemophilia A patient blood (Barrowcliffe et al., 2002). The differences in activity determined 
in these assays may indicate that while BDD-rFVIII can effectively replace plasma-derived- 
FVIII in the X-ase complex (as seen by the chromogenic assay), it differs from plasma- 
derived-FVIII in its interaction with other components of the coagulation cascade (as shown 
by the clotting assay). Some biochemical differences between plasma-derived-FVIII and 
BDD-rFVIII were previously observed at the early stages of BDD-rFVIII development, such 
as a five-fold more rapid thrombin cleavage of the BDD-rFVIII light chain at Arg1689 (Eaton 
et al., 1986) and a higher affinity of inactivated BDD-rFVIII to activated platelets in 
comparison with plasma-derived-FVIII (Li and Gabriel, 1997). The meta-analysis of the data 
accumulated during long-term clinical usage of ReFacto revealed its lower efficiency in 
prophylaxis, giving a 2.5-fold higher incidence of bleeding in comparison with full-length 
FVIII (Gruppo et al., 2003 and 2004). 
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1.5 Gene therapy for hemophilia A 
 
1.5.1 Overview 
 
The ambitious objective of gene therapy is to edit a defective gene sequence in situ to achieve 
complete reversion of a disease phenotype for the lifetime of the patient. In spite of recent 
successes in site-specific correction of defective gene sequences, the focus of most gene 
therapy strategies to date is on gene addition rather than gene replacement (Urnov et al., 
2005). This simplified approach relies on a delivery mechanism to provide a correct copy of 
the defective gene in somatic cells without removal of the error-containing genomic sequence. 
Hemophilia A and B are among the most extensively researched diseases in the field of gene 
therapy (Murphy and High 2008). Virtually every emerging gene delivery strategy, whether in 
vivo or ex vivo, viral or non-viral, has been tested in the hemophilia animal models (Kaufman 
1999). Gene transfer approaches for hemophilia are attractive because available clotting factor 
concentrates have not completely (1) allay the fears of possible viral contamination, specially 
plasma-derived concentrates, (2) alleviate chronic debilitating joint disease, or (3) resolve the 
extreme expense of replacement therapy (Azzi et al., 2001; Zakrzewska et al., Fischer et al., 
2001). Additional important factors driving interest in gene transfer approaches in hemophilia 
are (1) the detailed understanding of factor VIII gene, as well as structure, function, and 
biology of the factor VIII protein (Kaufman 1999); (2) the beneficial clinical effects expected 
to occur with even modest degrees of correction (1–5% of normal levels) (Nilsson et al., 
1992; Ljung 1999); (3) the availability of standardized coagulation assays to monitor factor 
expression; (4) the capacity of multiple target organs to secrete and perform the required post- 
translational modifications of FVIII (Yao et al., 1991; Arruda et al., 2001; Fakharzadeh et al., 
2000; Rosenberg et al., 2000); and (5) the availability of canine and mouse hemophilia 
models that phenotypically mimic the human disease ( Bi et al., 1995; Lin et al., 1997; Evans 
et al., 1989; Hough et al., 2002). 
 
Ex vivo and in vivo approaches are being pursued for hemophilia gene therapy. Ex vivo gene 
therapy involves the isolation of cells from the patient followed by expansion and genetic 
modification in culture with vectors expressing FVIII and subsequent re-administration of 
engineered cells to the patient. Successful ex vivo gene therapy requires efficient engraftment 
of the engineered cells leading to sustained FVIII production in circulation (Chuah et al. 
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2001). Different cell types have been considered as potential targets for ex vivo hemophilia 
gene therapy (Hortelano et al., 1996; Page and Brownlee 1997; Fakherzadeh et al., 2000). 
Roth et al., 2001 have used ex vivo-transduced fibroblasts to transfer factor VIII in patients 
with severe hemophilia A. Most ex vivo gene therapy strategies have relied on the use of 
retroviral vectors and to a more limited extent on non-viral gene transfer systems. 
Alternatively, in vivo gene therapy involves the administration of a gene transfer vector 
encoding FVIII directly to the patient leading to in situ genetic modification of the target 
cells. Intravenous administration of a FVIII vector would be a more cost-effective treatment 
than ex vivo protocols. However, the main disadvantage of in vivo gene therapy based on viral 
vectors is that a host immune response towards the viral vector would preclude vector re- 
administration, if more than one injection would be required to achieve therapeutic FVIII 
levels (Chuah et al., 2001). 
 
Hemophilia gene therapy requires the use of a gene delivery system that is efficient, safe, 
non-immunogenic and allows long-term gene expression. Both viral vectors as well as non- 
viral vectors have been considered for the development of hemophilia gene therapy (High 
2003). In general, viral-vector mediated gene transfer is far more efficient than non-viral gene 
transfer and is therefore the method of choice. The viral vectors are of retroviral, lentiviral, 
adenoviral and adeno-associated viral (AAV) origin, each with their own advantages and 
limitations (Chuah et al., 2001). 
 
Five different gene therapy Phase I clinical trials were initiated between 1998 and 2001 for 
the treatment of hemophilia using different gene delivery systems (Kay et al., 2000; Roth et 
al., 2001; Manno et al., 2003 and Powell et al., 2003). Three of them dealt with hemophilia 
A. The first was initiated by injecting a Moloney murine leukemia virus-based retroviral 
vector encoding B-domain deleted factor VIII. Doses ranging from 2.7 * 107 transducing units 
(TU)/kg to 4.4 * 108 TU/kg were tested. Factor VIII levels above 1% were sporadically 
detected but didn’t correlate with the dose administered; thus the signs of clinical 
improvement following vector infusion were modest at best (Powell et al., 2003). These 
findings were consistent with animal studies suggesting that efficient retroviral transduction 
of hepatocytes would require higher doses of viral vectors and a stimulation of cell division of 
hepatocytes. 
 
A second Phase I clinical trial was initiated to test the safety of a high capacity (gutless) 
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adenoviral vector encoding human factor VIII. Because of a priori concerns regarding 
immunogenicity, the trial was constructed to monitor carefully changes of liver function tests 
or platelet count. The first subject, enrolled at the lowest dose of 4.3 * 1010 vector particles 
(vp)/kg, experienced inflammation, fever and myalgia upon vector infusion; these symptoms 
are commonly observed with infusion of adenoviral vectors. The subject also experienced 
thrombocytopenia and an elevation in serum transaminases. The experiment resulted in 
having 1% of normal factor VIII levels for several months (Chuah et al., 2004). Due to safety 
concerns and disappointing results, no additional subjects were enrolled in this trial. 
 
One non-viral delivery method was also tested as a clinical trial (Roth et al., 2001) consisting 
of transplantation of factor VIII-transduced autologous fibroblasts. After isolation from skin 
biopsy, patient cells were transfected with a plasmid encoding a human factor VIII cDNA ex 
vivo and stable transfectants were selected. Single clones were expanded and tested for factor 
VIII expression level, as well as tumorigenicity and microbial safety. After reimplantation 
into the omentum, only a modest and temporary positive effect could be observed. The 
treatment was well tolerated and leaves the possibility of future attempts open using more 
potent expression systems for the ex vivo transduction and selection process. 
 
1.5.2 Adenoviruses as vectors for hemophilia A gene therapy 
 
Adenoviruses have several attractive features that make them particularly well suited for 
vector development and gene therapy. The genome has a size of 36 kb, which after (partial) 
deletion leaves a relatively large packaging capacity. Adenoviruses can infect and express 
genes at high levels in many different cell types and host cell replication is not required for 
expression, so nondividing cells such as hepatocytes are readily infected. There are at least 50 
different human serotypes, sub grouped A to G, which are commonly associated with mild 
diseases. Most adenoviral vectors currently used are derived from serotypes 2 and 5, which 
are endemic and cause upper respiratory tract infection (Chuah et al., 2001; Vorburger and 
Hunt, 2002). No known malignant tumors have resulted from adenovirus infection. Given that 
they have been used in live virus vaccine studies for many years without problems, they have 
a long-standing safety record (Thorrez et al., 2004). 
 
The difference between an adenovirus and its cognate vector is that the parental virus can 
replicate and infect other cells after infection, whereas adenoviral vectors can enter a cell, but 
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cannot use the cell to replicate. This impaired replication is due to the lack of at least one of 
the essential viral regulatory genes, which is replaced by the gene of interest, in our case 
FVIII. Although adenoviral vectors cannot replicate, they do retain all of the other essential 
properties, including the tropism of the parental viruses from which they are derived. 
Adenoviral vectors are relatively easy to manufacture at high concentrations (>1010 infectious 
units [iu] / mL) (Thorrez et al., 2004). They are well suited for hepatic gene delivery, but 
their main disadvantage is that the host immune response limits the duration of transgene 
expression and the ability to re-administer the vector (Schagen et al., 2004). A second 
inherent limitation to the duration of transgene expression is that the adenoviral DNA is not 
integrated into the host genome but is maintained episomally. Hence, dividing cells will 
gradually lose the adenoviral vector along with its potentially therapeutic gene. However, this 
also implies that there is virtually no risk of neoplastic transformation caused by insertional 
mutagenesis (Thorrez et al., 2004). 
 
The first-generation adenoviral vectors that were developed contained a deletion of the entire 
E1A and part of the E1B regions of the adenoviral genome (Kozarsky and Wilson 1993; 
Krougliak 1995) (Fig. 5A). This deletion allowed the insertion of an expression cassette up to 
8 kb. The E1 and other missing genes necessary for vector assembly are complemented in 
trans using appropriate packaging cells that express these genes (Berkner 1988). 
 
Acute and chronic toxic and lethal effects were observed frequently in nonhuman primates 
and other animals (including mice, rabbits and dogs) that receive high doses of replication- 
deficient adenoviral vectors (Connelly et al., 1996; Lozier et al., 1999). Several clinical trials 
based on adenoviral vectors had to be discontinued because of acute inflammatory responses 
and severe morbidity and mortality in some patients (National Institutes of Health 
Recombinant DNA Advisory Committee Assessment of adenoviral vector safety and toxicity, 
2002). 
 
This cellular immune response could be attenuated by further reducing viral gene expression. 
This was initially accomplished by alteration or deletion of additional early viral genes such 
as E2 or E4 (Armentano et al., 1995; Gao et al., 1996; Yeh et al., 1996) (Fig. 5B/C). Despite 
the fact that those second-generation vectors did not reveal any detectable de novo vector 
DNA synthesis or de novo viral gene expression in transduced cells, there was no significant 
difference in gene transfer and expression compared to first-generation adenoviral vectors 
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(Gorziglia et al., 1996). Further attenuation of the adenoviral vector backbone by removal of 
E1/E2/E3/E4 diminished vector toxicity further; however, the duration of transgene 
expression was reduced (Fig. 5D) (Andrews et al., 2001). 
 
High-capacity (HC) adenoviral vectors are the ultimate adenoviral vector modification which 
comprises a vector containing only the cis-acting elements necessary for replication and 
packaging, but lacking all adenoviral genes (Morral et al., 1999) (Fig. 5E). HC adenoviral 
vectors, also called gutted or gutless, fully-deleted (FD) and helper-dependent (HD) 
adenovectors can theoretically accommodate up to 37 kb of insert (Kochanek 1999; Schiedner 
et al., 1998; Parks and Graham 1997). Production of HC adenoviral vectors depends on the 
use of helper viruses that provide all missing functions in trans but cannot be packaged 
because of mutations in their packaging signal (Kochanek et al., 1996, Mitani et al., 1995; 
Clemens et al., 1996). As expected, High-capacity vectors give rise to prolonged transgene 
expression (Morsy et al., 1998; Schiedner et al., 1998; Balague et al., 2000; Zou et al., 2000) 
showing a significantly reduced acute and chronic hepatotoxicity as well as reduced 
inflammatory responses compared with first-generation adenoviral vectors (Schiedner et al., 
1998), even in large animal models such as primates or dogs (Morral et al., 1999; Chuah et 
al., 2003), which are more susceptible to the toxic side effects of adenoviral vectors than mice 
(Gallo-Pen et al., 2001; Schnell et al., 2001). 
 
The positive effect of HC vectors could be seen when comparing mice treated with HC 
vectors to mice treated with early generation vectors. HC vector-treated mice displayed 10- 
fold higher FVIII expression levels that were sustained for at least 9 months (Reddy et al., 
2002). It is not certain whether these vectors could give rise to life-long transgene expression 
because several studies demonstrated a slow but significant decline in transgene expression 
(Balague et al., 2000; Reddy et al., 2002). This may be due to the low turnover rate of 
hepatocytes leading to the gradual loss of the high- capacity adenoviral vector. The complete 
absence of de novo expression of adenoviral gene expression in the cells that are transduced 
with the HC adenoviral vectors is expected to prevent the induction of cytotoxic T 
lymphocytes (CTL), provided the transgene itself is non immunogenic. 
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Figure 5: Comparison of deletions in the adenoviral genome for different generations of adenoviral vectors. 
WT, wild type; HC, high capacity and ITR, inverted terminal repeats (Thorrez et al., 2004). 
 
1.5.3 Recombinant baculoviruses as efficient gene delivery systems 
 
Baculoviruses comprise a diverse group of arthropod viruses (Miller 1997). The best-studied 
member of this family, Autographa californica nuclear polyhedrosis virus (AcMNPV) is a 
large enveloped virus with a double-stranded, circular DNA genome of around 130 kb. 
Baculoviruses usually possess a rod shaped capsid (40 to 50 nm in diameter and 200 to 400 
nm in length). Within the protein capsid, the nucleoprotein core contains the condensed DNA 
genome (O’Reilly et al., 1992). The complete sequence of the viral genome has been 
determined (Ayres et al., 1994). The application of recombinant baculoviruses for the 
expression of recombinant proteins in insect cells was first described in the early 1980s 
(Smith et al., 1983; Pennock et al., 1984). Since these initial reports, the baculovirus insect 
cell expression system has been extensively developed and used for the production of 
numerous recombinant proteins in insect cells (O’Reilly et al., 1994; Kost et al., 2000). The 
most commonly used insect host cell lines are the Sf9 and Sf21AE lines originally derived 
from Spodoptera frugiperda pupal ovarian tissue (Vaughn et al., 1977) and the BTI-Tn-5B1-4 
line, also known as ‘High 5 cells’, derived from Trichoplusia ni egg cell homogenates 
(Granados et al., 1994). 
 
Besides expression of proteins, the baculovirus AcMNPV has been recently reported to work 
as a functional vector for gene delivery in mammalian cells of various origins (Kost and 
Condreay 2002; Pieroni and La Monica, 2001; Sandig and Strauss, 1996). Several years ago, 
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baculovirus was shown to infect hepatic cell lines and express foreign genes under the control 
of mammalian promoters (Boyce et al., 1996; Hofmann et al., 1995). Subsequently, 
recombinant baculoviruses has been shown to transduce foreign genes into additional cell 
lines, including those of non-hepatic origin (Shoji et al., 1997). 
 
The use of recombinant baculovirus vectors for gene delivery in mammalian cells has been 
widely documented over the last few years. Baculovirus has been demonstrated to be a very 
efficient vector in a variety of cell lines due to a general non-tissue-specific uptake 
mechanism, and transcription machinery regulated intracellularly by epigenetic factors. Its 
large insert capacity, the ease of production at high titer and the lack of cytotoxicity are the 
basic feature of this vector. This vector has been successfully used for therapeutic studies in 
vitro (e.g. the testing of antiviral compounds) or ex vivo (e.g. anticancer therapy) but has also 
been developed as a safe and efficient vector suitable for in vivo gene therapy. The most 
recent examples of gene delivery in vivo in liver, skeletal muscle and the central nervous 
system of mice and rats shows that it is worth to further develop baculovirus-derived vectors 
capable to prolong in vivo gene expression. Baculoviral vectors are suitable for the treatment 
of acquired or inherited diseases in humans (Pieroni and La Monica, 2001). Since baculovirus 
promoters are silent in mammalian cells, no virus replication occurs. In addition, no cytotoxic 
effects mediated by this virus in mammalian cells have been reported (Sollerbrant et al., 
2001). 
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1.6 Objectives of the study 
 
1.6.1 Functional studies on factor VIII protein variants containing different lengths of 
the B-domain 
 
The aim of this part of the study is to evaluate the importance and the effect of the B domain 
region on factor VIII (FVIII) expression and activity and to generate a B-domain deleted 
recombinant FVIII (BDD-rFVIII) containing the minimal B-domain sequence required for 
optimal thrombin binding and FVIII activation. This BDD-rFVIII should show the minimal 
(or no) discrepancy between the clotting assay and the chromogenic activity assay. 
 
For this purpose, several FVIII expression plasmids containing various lengths of the B- 
domain (approximately 100, 200, 300, 400 amino acids starting from the amino terminus of 
the B domain) as well as a B-domain deleted construct will be constructed and expressed 
transiently and stably. FVIII activity should be assessed in culture medium and from purified 
products, whereas FVIII antigen should be assessed from culture medium and cellular lysates. 
Purified FVIII products will also be cleaved by thrombin and analysed by western blotting. 
 
FVIII constructs should be expressed at the beginning in three mammalian cell lines (COS-7, 
HEK 293T and CHO) and the cell line that shows the highest expression level in terms of 
FVIII activity level in culture medium should then be used for further expression and 
functional analysis of the constructs. Additionally, the constructs should also be expressed 
stably in CHO-DHFR[-] cell line. 
 
To evaluate the importance of the B-domain region, the different FVIII constructs (containing 
different lengths of the B-domain) should be compared to the BDD construct in terms of: 1) 
Activity level using clotting and chromogenic assays, 2) Assay discrepancy of both activity 
assays, 3) Expression level in terms of the total amount of FVIII produced; in medium as well 
as trapped inside cells), 4) Functionality in terms of FVIII specific activity and 5) FVIII 
activation by thrombin. 
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1.6.2 Construction of a new helper vector for the production of helper-dependent 
adenovectors for the use in hemophilia gene therapy 
 
The aim of this part of the study is to design a novel helper system for the production of a 
helper-dependent adenovector (HD-AdV) carrying a B-domain-deleted factor VIII-cDNA 
without any contamination with a helper virus. For this, a packaging deficient, replication- 
competent adenovirus Helper genome will be delivered to the HD-AdVs containing cells by a 
recombinant Baculovirus / Adenovirus hybrid. This Helper genome should provide (in trans) 
all of the functions necessary for the propagation of HD-AdVs. 
 
In designing our novel helper genome, we will use only Ad5 genes (nts 4000 to 35832) 
necessary for replication and packaging of HD-AdV. The helper genome will be deleted of 
the 5'ITR (nts 1-190), the packaging signal (nts 191-358), the 3'ITR (nts 35833-35935) and 
the E1/E3 region, thus rendering it replication incompetent and packaging incompetent. As 
the replication of the Ad5 helper genome will result in HD-AdV production, its replication 
will be achieved by fusing the AAV2-ITRs (5'ITR; 3'ITR) into the helper genome construct. 
AAV2-ITRs can then serve as origins of replication given that the AAV2-rep78/68 genes are 
provided in trans. 
 
For augmentation of this DNA construct, (AAV2[5'ITR] /Ad5/ AAV2[3'ITR]), it will be 
integrated into the Baculovirus genome. This hybrid helper vector "Bac-AAV2-Ad5" can then 
be propagated to high titers in Sf9 insect cells. 
 
Once the Bac-AAV2-Ad5 helper virus is produced, it can be used to rescue the HD-AdV in 
HEK 293 cells. For this, HEK 293 cells, already transfected with the HD-AdV, will be 
infected with Bac-AAV-Ad5 and Bac-AAV2-Rep (a baculoviral construct carrying the 
Rep78/68 genes) viruses. Inside the cells, the AAV2-ITRs should function as an origin of 
replication and as a termination signal supported by the Rep78/68 protein synthesized by Bac- 
AAV2-Rep virus. Additionally, the Ad5 genome of the helper vector will provide all Ad5 
proteins necessary for replication and packaging of HD-AdV. 
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2. Materials and methods: 
 
2.1 Materials 
 
2.1.1 Chemicals and reagents 
 
Chemicals and reagents used in this study are listed below in alphabetical order after the 
supplier's name. All chemicals were of analytical grade. 
 
Applied Biosystems    BigDye terminator; Template suppression reagent 
(Weiterstadt) 
 
Bio-Rad      PVDF membrane; Precision protein standards;  
(Muenchen)    (10-250Kda); 7.5% SDS-PAGE gels 
 
Biozym      Agarose LE 
(Hess. Oldendorf)  
 
Dade Behring    Human FVIII-deficient plasma;   
(Marburg)     Lyophilized standard human plasma 
 
Diagnostica Stago    Asserachrom VIII:CAg 
(France) 
 
Fermantas      1 Kb DNA ladders 
(St.Leon-Rot)  
 
Fluka      Chloroform:isoamylalcohol (24:1); chloroform; 
(Neu Ulm)     Formamide; Formaldehyde; SDS; Ethidium bromide 
      (10 mg/ml); glycine; Tris base; Nonidet-P40; Luminol 
 
GE Healthcare     FVIII-select; PD-10 columns; PD-10 buffer reservoir 
(Freiburg) 
 
Invitrogen      All tissue culture media; EDTA-Trypsin; D-PBS; 
(Leek, Niederland)   Phenol:chloroform:isoamylalcohol (25:24:1); Platinum 
      Taq DNA polymerase; EDTA; Ethanol; Methanol; 
      Isopropanol; Glycerol; Sodium chloride; Sodium acetate; 
      Sodium citrate; Lipofectamine 2000; Cellfectin; Penicillin/ 
      streptomycin solution (100x) DH5α competent cells; 
      HT supplement (50x); Trizol; SuperScript III Reverse  
      Transcriptase 
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Millipore     Ultracel-30K Amicon ultra centrifugal filters  
(Ireland) 
 
New England Biolabs    All restriction enzymes, 1 Kb DNA ladder 
(Schwalbach/Taunus) 
 
Nunc Nalgene     Tissue culture dishes, plates, flasks and pipettes 
(Wiesbaden) 
  
PeqLab      Pwo DNA polymerase 
(Erlangen)  
 
Qiagen       Mini- and Maxi-Plasmid kits; DNeasy kit; Gel Extraction  
(Hilden)     kit 
 
Roche      dNTP mix (10 mM); Expand long template PCR Kit; 
(Mannheim)    Proteinase K; BSA (20 mg/ml); DNA molecular weight 
      marker X ; T4 DNA ligase; SAP; Klenow enzyme; 
      CompleteTM protease inhibitor cocktail 
 
Sartorius stedim biotech   Vivaspin 20 columns (30,000 MWCO) 
(Gottingen) 
 
Sigma      Cesium chloride; DMSO; Tween 20; LB broth and Agar; 
(Deisenhofen)    Ampicillin; p-Coumaric acid; Methotrexate; Dialyzed  
      FBS; Insect cell culture tested FBS; DEPC 
 
Stratagene      Competent cells (XL10-Gold, BJ5183) 
(Heidelberg)  
 
Thermoscientific    Pierce centrifuge columns (~30µm pore size) 
 (USA) 
 
2.1.2 Buffers and solutions 
 
Buffer A     20 mM Imidazol 
      1 M Sodium chloride 
      20 mM Calcium chloride 
      200 ppm Tween-80 
 
Buffer B     20 mM Imidazol 
      1.5 M Sodium chloride 
      50% Ethylene glycol 
      20 mM Calcium chloride 
      200 ppm Tween-80 
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Cell lysis buffer    20 mM Tris-HCL, pH 8.0 
      150 mM Sodium chloride 
     1 mM EDTA 
     0.5 % Nonidet-40 
     CompleteTM protease inhibitor cocktail(added before Use) 
 
DNA gel loading buffer  0.25 % Bromophenol blue 
       40 % (w/v) Sucrose in water 
 
Laemmli sample buffer  62.5 mM Tris-HCL, pH 6.8 
      25 % Glycerol 
      2 % SDS 
      0.01% Bromophenol blue 
      Add 50 µl of β-Mercaptoethanol per 950 µl buffer Before  
      use 
 
Protein electrode running  250 mM Tris base, pH 8.3   
buffer (10x)    1.92 M Glycine 
      1 % SDS 
 
Solution I     15 mM Tris-HCL, pH 8.0 
      10 mM EDTA 
      100 µg/ml RNase A 
 
Solution II      0.2 N Sodium hydroxide 
      1% SDS 
 
Solution A     0.1 M Tris-HCl, pH 8.6, 200 ml 
      50 mg Luminol 
 
Solution B      DMSO, 10 ml 
      11 mg para-Hydroxycoumaric acid 
 
TAE (50x)     2 M Tris-base (pH 8.0) 
      1 M Glacial acetic acid 
      0.05 M EDTA (pH 8.0) 
 
TBS (10x)      200 mM Tris base, pH 7.6 
      1.379 M Sodium citrate 
 
Thrombin buffer (10x)   200 mM Tris-HCl. pH 8.4 
      1.5 M NaCl 
      25 mM CaCl2 
 
TE buffer      10 mM Tris (pH 8.0) 
      1 mM EDTA 
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Western blocking buffer  1x TBS 
      0.1 % Tween-20 
              5 % Skimmed milk 
 
Towbin (Transfer)   25 mM Tris base, pH 8.3 
 buffer     192 mM Glycine  
      20 % Methanol 
 
 
 
 
2.1.3 Primers 
 
All primers are in 5'-3' –orientation. Sense primers end up with (s) while antisense ones with 
(a). 
 
 
2.1.3.1 Primers used in the construction of B-domain deleted expression plasmids 
 
 
Table 1: Primers used in the construction of B-domain deleted expression plasmids.  
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2.1.3 Primers 
 
All primers are in 5'-3' –orientation. Sense primers end up with (s) while antisense ones with 
(a). 
 
2.1.3.1 Primer  used in the construction of B-domain deleted expression plasmids 
 
Primer name Primer sequence 
pMTF8-6085Ns CAT CGA CGT ACT TCG CGA CTG TGC TCT CAA AAC CCA CC 
pMTF8-6068SNs GCT CAG CAA CTA GTT GCC ATC GAC GTA CTT CGC GAC TG 
pMTF8-7310Aa ATC CGG AAT AAT GAA GTC TGG CCA GC 
pMTF8-3369Na CTA TGG ACT TCG CGA GAA GCT TCT TGG TTC AAT GGC 
pMTF8-3671Na GTA TAC TCT TCG CGA GTG ATG GAG CTG TGG CCT GAA G 
pMTF8-3973Na GAC GAC GCT TCG CGA ATC ATT ATT TTC TTC ACT CAA G 
pMTF8-4243Na GAC GAC GCT TCG CGA TTC TAA TAT ATT TTG CCA GAC TG 
pMTF8-4551Na CAG GAC TCT TCG CGA TTT TTC TGG TCC TAA GGA TAC 
pMTF8-1689s CTT GAA TTC AGG CCT CAT TGG AGC C 
Table 1: Primers used in the construction of B-domain deleted expression plasmids. 
 
2.1.3.2 Primers used in verifying the constructed B-domain deleted expression plasmids 
 
Primer name Primer sequence 
FVIII-210a AAG GCA CAG AAA GAA GCA GG 
FVIII-172s ATG CAA ATA GAG CTC TCC ACC 
FVIII-681s ACT GTG CCT TAC CTA CTC AT 
FVIII-1203s AGT AGA CAG CTG TCC AGA GG 
FVIII-1770s AGT GAC TGT AGA AGA TGG GC 
FVIII-2311s TCA GAC TTT CGG AAC AGA GG 
FVIII-2821s ACA ACT GCA GCA ACA GAG TTG 
FVIII-3297s GAA TAG TCC ATC AGT CTG GC 
FVIII-3862s CCT CAG ATA CAT ACA GTG AC 
FVIII-4381s AGA TCT CCA TTA CCC ATT GC 
FVIII-4906s AAG CTA TTG GAT CCT CTT GC 
FVIII-5406s TGT CCC TCA GTT CAA GAA AG 
FVIII-5941s TCC CTG CAA TAT CCA GAT GG 
FVIII-6501s GAA GTT CTC CAG CCT CTA CA 
FVIII-7001s AGG AGT TCC TCA TCT CCA GC 
pMT2-487s TCC ACT CGC TCC AGG GTG 
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2.1.3.2 Primers used in verifying the constructed B-domain deleted expression plasmids 
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Table 1: Primers used in the construction of B-domain deleted expression plasmids. 
 
2.1.3.2 Primers used in verifying the constructed B-domain deleted expression plasmids 
 
Primer name Primer sequence 
FVIII-210a AAG GCA CAG AAA GAA GCA GG 
FVIII-172s ATG CAA ATA GAG CTC TCC ACC 
FVIII-681s ACT GTG CCT TAC CTA CTC AT 
FVIII-1203s AGT AGA CAG CTG TCC AGA GG 
FVIII-1770s AGT GAC TGT AGA AGA TGG GC 
FVIII-2311s TCA GAC TTT CGG AAC AGA GG 
FVIII-2821s ACA ACT GCA GCA ACA GAG TTG 
FVIII-3297s GAA TAG TCC ATC AGT CTG GC 
FVIII-3862s CCT CAG ATA CAT ACA GTG AC 
FVIII-4381s AGA TCT CCA TTA CCC ATT GC 
FVIII-4906s AAG CTA TTG GAT CCT CTT GC 
FVIII-5406s TGT CCC TCA GTT CAA GAA AG 
FVIII-5941s TCC CTG CAA TAT CCA GAT GG 
FVIII-6501s GAA GTT CTC CAG CCT CTA CA 
FVIII-7001s AGG AGT TCC TCA TCT CCA GC 
pMT2-487s TCC ACT CGC TCC AGG GTG 
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pMT2-962s GAG GTG TGG CAG GCT TGA GAT CTG 
pMT2-1131a CCG TCA AGT TTG GCG CGA AAT C 
pMT2-1564a CTG GTT GAT TCA TGG CTT C 
pMT2-1480s GAA CAA CCG GAA TTG GCA AG 
pMT2-2369s GCT CCA TGG TCG GGA CGC TCT G 
pMT2-5109s CGA CGG CCA GTG CCA AGC 
Table 2: Primers used in verifying the constructed B-domain deleted expression plasmids. 
 
2.1.3.3 Primers used for construction and verifying the plasmid, bacmid and viral 
constructs of Bac-AAV2-Ad5, Bac-AAV2-Rep and Bac-EGFP  
 
Primer name Primer sequence 
AAV2-321s ATG CCG GGG TTT TAC GAG 
AAV2-1382s CGG GTG CGT AAA CTG GAC 
AAV2-289MLs GGT CTC AAC ACG CGT TTG AAG CGG GAG GTT TGA ACG 
AAV2-2310NHa GGA TAT CAA GCT AGC CTC TGC GGG CTT TGG TGG TGG 
Ad5-4231a CTC TGC AGT GGT GCT ACC 
Ad5-35823a GGC GGA GTA ACT TGT ATG TG 
Ad5-35832Bga CGG CTG ACA GAT CTG TTT TAG GGC GGA GTA ACT TGT 
Ad5-34943s TGG GCG GCG ATA TAA AAT GC 
Ad5-4000Bgs CGT TGA CTA GAT CTG AAG GCT TCC TCC CCT CCC AAT GC 
CMV-1Ecos CGT CGC GAA TTC TTA GTT ATT AAT AGT AAT CAA TTA C 
GFP-1329Ha CTT GTG AAG CTT TTA CTT GTA CAG CTC GTC CAT GCC 
MMTV-591Bsps GAC GCG CTG TCC GGA GTC CCT AGA AGT AAA AAA GGG 
MMTV-1347Bama GTA TCA TAT GGA TCC CCG ACC TGA GGG TGA CCG GGA 
BGH-2532NMBs GCG CGG ATC CAC GCG TCG TAT GCT AGC TAG CCT GTG CCT 
TCT AGT 
BGH-2916EcoRa GCA GCG CCT GAA TTC CAA GGG ACA TCT TCC CAT TC 
M13F GTTTTCCCAGTCACGAC 
M13R CAGGAAACAGCTATGAC 
Table 3: Primers used in the construction and verification of plasmid and bacmid baculovirus 
recombinant vectors. 
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2.1.3.3 Primers used for construction and verifying the plasmid, bacmid and viral 
constructs of Bac-AAV2-Ad5, Bac-AAV2-Rep and Bac-EGFP 
 
 
Table 3: Primers used in the construction and verification of plasmid and bacmid baculovirus recombinant 
vectors. 
 
 
2.1.4 Cell lines and culture media 
 
 
Table 4: Cell lines and culture media * All media contain Glutamax and were obtained from Invitrogen. 
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pMT2-962s GAG GTG TGG CAG GCT TGA GAT CTG 
pMT2-1131a CCG TCA AGT TTG GCG CGA AAT C 
pMT2-1564a CTG GTT GAT TCA TGG CTT C 
pMT2-1480s GAA CAA CCG GAA TTG GCA AG 
pMT2-2369s GCT CCA TGG TCG GGA CGC TCT G 
pMT2-5109s CGA CGG CCA GTG CCA AGC 
Table 2: Primers used in verifying the constructed B-domain deleted expression plasmids. 
 
2.1.3.3 Primers used for construction and verifying the plasmid, bacmid and viral 
constructs of Bac-AAV2-Ad5, Bac-AAV2-Rep and Bac-EGFP  
 
Primer name Primer sequence 
AAV2-321s ATG CCG GGG TTT TAC GAG 
AAV2-1382s CGG GTG CGT AAA CTG GAC 
AAV2-289MLs GGT CTC AAC ACG CGT TTG AAG CGG GAG GTT TGA ACG 
AAV2-2310NHa GGA TAT CAA GCT AGC CTC TGC GGG CTT TGG TGG TGG 
Ad5-4231a CTC TGC AGT GGT GCT ACC 
Ad5-35823a GGC GGA GTA ACT TGT ATG TG 
Ad5-35832Bga CGG CTG ACA GAT CTG TTT TAG GGC GGA GTA ACT TGT 
Ad5-34943s TGG GCG GCG ATA TAA AAT GC 
Ad5-4000Bgs CGT TGA CTA GAT CTG AAG GCT TCC TCC CCT CCC AAT GC 
CMV-1Ecos CGT CGC GAA TTC TTA GTT ATT AAT AGT AAT CAA TTA C 
GFP-1329Ha CTT GTG AAG CTT TTA CTT GTA CAG CTC GTC CAT GCC 
MMTV-591Bsps GAC GCG CTG TCC GGA GTC CCT AGA AGT AAA AAA GGG 
MMTV-1347Bama GTA TCA TAT GGA TCC CCG ACC TGA GGG TGA CCG GGA 
BGH-2532NMBs GCG CGG ATC CAC GCG TCG TAT GCT AGC TAG CCT GTG CCT 
TCT AGT 
BGH-2916EcoRa GCA GCG CCT GAA TTC CAA GGG ACA TCT TCC CAT TC 
M13F GTTTTCCCAGTCACGAC 
M13R CAGGAAACAGCTATGAC 
Table 3: Primers used in the construction and verification of plasmid and bacmid baculovirus 
recombinant vectors. 
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2.1.4 Cell lines and culture media 
 
Cells Culture Medium* Source of cells 
HEK 293T DMEM high glucose AG Prof. W Poller (Freie Universität, Berlin) 
COS-7 DMEM high glucose DSMZ (Braunschweig) 
CHO-DHFR[-] IMDM + HT supplement DSMZ (Braunschweig) 
Sf9 Grace's supplemented ATTC (Manassas, VA, USA) 
Table 4: Cell lines and culture media 
* All media contain Glutamax and were obtained from Invitrogen. 
        
2.1.5 Plasmids and Vectors 
 
Name Source 
pMT2-FVIII Dr Rainer Schwaab (Srour et al., 2008) 
pFastBac-1 Invitrogen (Leek, Niederland) 
pShuttle-CMV Stratagene (Heidelberg) 
pAdEasy-1 Stratagene (Heidelberg) 
pTRUF5 Prof. Kleinschmidt (DKFZ, Heidelberg) 
Mini-Ad5 Dr Stefan Kochanek (Uniklinik Ulm) 
pDG Prof. Kleinschmidt (DKFZ, Heidelberg) 
pTRE-Luc-Ad5 BD Clontech (Palo Alto, USA) 
pEGFP-C1 BD Clontech (Palo Alto, USA) 
Table 5: Plasmids and vectors. 
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2.1.5 Plasmids and Vectors 
 
 
Table 5: Plasmids and vectors. 
 
 
2.2 Molecular biology methods 
 
2.2.1 Isolation of plasmid DNA, bacmid DNA and extra chromosomal DNA 
 
Plasmid DNA was isolated from E.coli cultures (DH5α strain; Invitrogen and BJ5183; 
Stratagene) grown in LB broth at 37°C by shaking at 225 rpm for 16 hours. Ampicillin 
(50µg/ml) was used as a selection agent. Mini- and Maxi-plasmid preparations were 
performed depending on further use of the plasmid. For plasmid analysis by PCR, restriction 
mapping or DNA sequencing the QIAprep Spin Miniprep kit (Qiagen) was used. If plasmid 
was isolated for use in cell culture transfection experiments, the QIAGEN Plasmid Maxi kit 
(Qiagen) was used. Plasmid isolation was performed according to the instructions of the kit 
supplier. 
 
Bacmid DNA was isolated from E.coli cultures (DH10Bac strain; Invitrogen) grown in LB 
broth at 37°C by shaking at 225 rpm for 16 hours. Kanamycin (50 µg/ml), gentamicin (7 
µg/ml) and tetracycline (10 µg/ml) were used as selection agents. Bacmid isolation was 
performed according to the Bac-to-Bac Baculovirus Expression System manual (Invitrogen). 
Briefly, 1.5 ml bacterial culture was centrifuged at 14.000 x g for 1 min. The cell pellet was 
resuspended in 300 µl of Solution I, gently mixed and a 300 µl Solution II was then added, 
gently mixed and incubated at RT for 5 min. Slowly and while mixing gently 0.3 ml of 3 M 
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Table 4: Cell lines and culture media 
* All media contain Glutamax and were obtained from Invitrogen. 
        
2.1.5 Plasmids and Vectors 
 
Name Source 
pMT2-FVIII Dr Rainer Schwaab (Srour et al., 2008) 
pFastBac-1 Invitrogen (Leek, Niederland) 
pShuttle-CMV Stratagene (Heidelberg) 
pAdEasy-1 Stratagene (Heidelberg) 
pTRUF5 Prof. Kleinschmidt (DKFZ, Heidelberg) 
Mini-Ad5 Dr Stefan Kochanek (Uniklinik Ulm) 
pDG Prof. Kleinschmidt (DKFZ, Heidelberg) 
pTRE-Luc-Ad5 BD Clontech (Palo Alto, USA) 
pEGFP-C1 BD Clontech (Palo Alto, USA) 
Table 5: Plasmids and vectors. 
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K+-acetate (pH 5.5) was added and the mixture was cooled on ice for 10 min. After 10 min 
centrifugation at 14.000 x g, the supernatant was transferred to a new microcentrifuge tube 
containing 0.8 ml isopropanol, gently inverted several times and cooled on ice for 10 min. 
The sample was then centrifuged at 14.000 x g for 15 min. and the pellet was washed with 0.5 
ml 70% ethanol, and centrifuged for 5 min at 14.000 x g. The DNA pellet was then air dried 
at RT for 5 to 10 min and dissolved in 40 µl of TE buffer. 
 
Extra chromosomal DNA was isolated from mammalian cells using a modified Hirt 
procedure (Arad, 1998). Trypsinized cells (106-107) were suspended in 250 µl 50 mM Tris-
HCL (pH 7.5), 10 mM EDTA containing 100 µg/ml RNase A and lysed by the addition of 
250 µl 1.2% SDS. The suspension was gently mixed and allowed to stand at RT for 5 min. 
Cellular debris and chromosomal DNA were precipitated by the addition of 350 µl of 3 M 
CsCl, 1 M K+- acetate and 0.67 M acetic acid. The suspension was then gently mixed and 
incubated on ice for 15 min. After centrifugation at 14.000 x g, the supernatant was loaded 
onto a QIAprep Spin Column (Qiagen). The column was washed with 750 µl 80 mM K+-
acetate, 10 mM Tris- HCL (pH 7.5), 40 µM EDTA and 60% ethanol. DNA was then eluted 
with 50µl TE buffer or ddH2O. 
 
To gain a very pure DNA, samples were extracted with phenol/chloroform for the removal of 
proteins (e.g. enzymes) or to reduce salt concentration. DNA samples were suspended in 200 
µl ddH2O and extracted once with one volume of phenol: chloroform: isoamylalcohol (ratio 
25:24:1) followed by centrifugation at 3.000 rpm for 5 min. The upper layer containing the 
DNA was precipitated by adding 0.1 volume of 3M Na+-acetate (pH 4.8) and two volumes of 
prechilled ethanol, and allowed to stay at -80°C for at least 30 min. After centrifugation at 
14.000 rpm for 15 min, the DNA pellet was washed once with 1 ml of 70 % prechilled 
ethanol, vacuum dried and dissolved in TE buffer or ddH2O. 
 
2.2.2 Isolation of total RNA from cells grown in monolayers 
 
Total RNA was prepared from monolayer cell cultures using Trizol reagent according to the 
supplier recommendations. Cells were washed with ice cold PBS then lysed by adding Trizol 
reagent (1 ml per 10 cm2) and scraped with cell scraper. Cell lysate was then passed several 
times through a pipette and vortexed thoroughly. Homogenized samples were incubated 5 min 
at room temperature and centrifuged to remove cell debris. Supernatants were then mixed 
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with chloroform (0.2 ml per 1.0 ml Trizol), vortexed vigorously for 15 seconds and then 
incubated at room temperature for 2 to 3 min. After centrifugation at 12,000 xg at 4 °C for 15 
min, the upper aqueous phase containing RNA were moved carefully into a fresh tube. RNA 
was then precipitated by mixing with isopropanol (0.5 ml per 1.0 ml Trizol), incubating at 
room temperature for 10 min and centrifugation at 12000 xg at 4 °C for 10 min. RNA pellet 
was then washed once with 75% ethanol and air or vacuum dried and dissolved in DEPC- 
treated water. 
 
2.2.3 Measurement of isolated DNA/RNA concentrations 
 
DNA and RNA concentration was determined by measuring OD at 260 nm, where 1.0 OD 
represents 50 µg DNA/ml and 40 µg RNA/ml (Sambrook and Russell, 2001). 
 
 
2.2.4 Agarose gel electrophoresis 
 
Nucleic acids were separated according to their size in agarose gel matrix by electrophoresis. 
The concentration of agarose varied (0.6-2%) depending on the size of the DNA fragments 
expected. Ethidium bromide (0.5 µg/ml) was included in the agarose gel for visualization of 
the DNA fragments under UV (λ 302 nm) light (Sambrook et al., 1989). Samples were mixed 
with gel loading buffer before loading in the gel. The gels were run at 100-150 V in 1x TEA 
buffer. DNA molecular weight markers or ladders (marker X [Roche] and 1 kb ladders 
[Fermentas and New England Biolabs]) were used to determine the size of DNA fragments. 
 
2.2.5 PCR 
 
An analytical and preparative polymerase chain reaction (PCR) was used. Anaytical PCR was 
performed using Platinum Taq DNA polymerase (Invitrogen) and was used to analyze 
plasmids, bacmids and baculovirus plaques. Preparative PCRs were performed using the 
proof reading Pwo DNA polymerase (PeqLab) and generated fragments were used for 
cloning. For DNA fragments longer than 2 kb, a preparative long distance (LD) PCR was 
performed using a mixture of Pfu (a proof reading polymerase) and Taq DNA polymerase 
(Roche). The fidelity of Pfu and Pwo is 12x and 10x more effective than Taq, respectively.  
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Typical PCR reactions are shown in following table: 
 
 
Table 6: Constituents of PCR reactions using different amplification enzymes.  
*All primers used are listed in section II.1.3. 
 
 
Thermal cycling of PCR using Taq and Pwo were as follows: 5 min initial denaturation at 
94°C followed by 35 cycles [each cycle consisted of denaturation at 94°C for 30 sec, 
annealing at 50-60°C for 30 sec, and extension at 72°C for 1min/kb (with a time increment of 
20 sec/cycle in the last 20 cycles for Pwo)]; and a final extension step at 72°C for 10 min. 
 
The LD PCR was performed as follows: initial denaturation at 94°C for 2 min. followed by 30 
cycles [each consisted of denaturation 94°C for 10 sec, annealing at 60-62°C for 30 sec with 
time decrement of 0.2°C/cycle, and extension at 68°C for 1 min/kb (with a time increment of 
20 sec/cycle for the last 20 cycles)] and a final extension at 68°C for 7 min. The annealing 
temperature used depends on the melting temperature of the primers. PCRs were performed 
using GeneAmp PCR system 9700, Perkin Elmer. 
 
For purification, the PCR products were subjected to agarose gel electrophoresis as described 
in section II.2.3 and the target DNA band was then excised and purified using the QIAquik 
Gel extraction kit (Qiagen) according to the instructions of the kit supplier. 
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 2.2.4 Agarose gel electrophoresis 
 
Nucleic acids were separated according to their size in agarose gel matrix by electrophoresis. 
The concentration of agarose varied (0.6-2%) depending on the size of the DNA fragments 
expected. Ethidium bromide (0.5 !g/ml) was included in the agarose gel for visualization of 
the DNA fragments under UV (" 302 nm) light (Sambrook et al., 1989). Samples were mixed 
with gel loading buffer before loading in the gel. The gels were run at 100-150 V in 1x TEA 
buffer. DNA molecular weight markers or ladders (marker X [Roche] and 1 kb ladders 
[Fermentas and New England Biolabs]) were used to determine the size of DNA fragments.  
 
 
2.2.5 PCR 
 
An analytical and preparative polymerase chain reaction (PCR) was used. Anaytical PCR was 
performed using Platinum Taq DNA polymerase (Invitrogen) and was used to analyze 
plasmids, bacmids and baculovirus plaques. Preparative PCRs were performed using the 
proof reading Pwo DNA polymerase (PeqLab) and generated fragments were used for 
cloning. For DNA fragments longer than 2 kb, a preparative long distance (LD) PCR was 
performed using a mixture of Pfu (a proof reading polymerase) and Taq DNA polymerase 
(Roche). The fidelity of Pfu and Pwo is 12x and 10x more effective than Taq, respectively. 
Typical PCR reactions are shown in following table: 
 
Components Final concentrations 
PCR type Taq Pwo LD (Pfu + Taq) 
10x buffer, -Mg2+ 1x 1x 1x 
MgCl2 50 mM 1.5 mM -- 2.25 mM 
MgSO4 25mM -- 4 mM -- 
dNTPs 10 mM 200 !M 400 !M 500 !M 
Sense primer* 100 !M 1 !M 1 !M 0.33 !M 
Antisense primer* 100 !M 1 !M 1 !M 0.33 !M 
Polymerase 1 U 1 U 2.5 U 
Template 50-200 ng 50-200 ng 10-30 ng 
ddH2O Up to 25 !l Up to 50 !l Up to 50 !l 
Table 6: Constituents of PCR reactions using different amplification enzymes. 
*All primers used are listed in section II.1.3. 
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2.2.6 DNA sequencing 
 
DNA sequencing was performed to analyze plasmids, bacmids, baculoviruses and to verify 
DNA fragments before and after cloning. A cycle sequencing reaction was performed by 
mixing DNA template (100-200 ng PCR product or 200-500 ng plasmid DNA) with 20 pmol 
of sense or antisense primer, 2 µl of BigDye terminator (contains fluorescent labeled ddNTPs, 
dNTPs, AmpliTaq DNA polymerase FS and Taq buffer) from Applied Biosystems and 
ddH2O to a total volume of 10 µl. The thermal cycling was performed using GeneAmp PCR 
system 9700 (Perkin Elmer) as follows: initial denaturation at 96°C for 2 min followed by 25 
cycles (each consist of 10 sec denaturation at 96°C, 5 sec annealing at 50-55°C and 4 min 
extension at 60°C). 
Cycle sequencing products were purified by mixing them with 90 µl ddH2O, 250 µl ethanol 
and 10 µl of 3 M Na+-acetate (pH 4.6), followed by precipitation at 14.000 rpm for 15 min. 
The pellet was then washed once with 70% ethanol, vacuum dried, resuspended in 20 µl 
Template Suppression Reagent (TSR; Applied Biosystems), denatured at 90°C for 2 min, 
chilled on ice and subjected to sequencing using the ABI Prism 310 Genetic Analyzer (Perkin 
Elmer). 
 
2.2.7 DNA restriction and ligation 
 
DNA fragments, intended for cloning, were generated by PCR (section II.2.4) and included 
restriction site linkers that were created and inserted into the 5'-end of the respective primers. 
The DNA fragment (insert) and the plasmid (to be cloned in it) were restricted with restriction 
enzymes (RE). The restriction reaction which included 0.2-1.0 µg of DNA, 5-10 units of RE 
and 1x RE buffer was incubated at 37°C for 1-2 hours. RE and their buffers were obtained 
from New England Biolabs. The RE reaction was scaled up according to the amount of DNA 
needed. The restricted DNA fragments were then purified by phenol/chloroform or agarose 
gel electrophoresis purification. Restricted fragments were blunt ended when needed with 
Klenow fragment (Roche). Before ligation, restricted DNA fragments with blunt ends or 
complementary cohesive ends were dephosphorylated by shrimp alkaline phosphatase (SAP) 
to prevent self-ligation. Dephosphorylation was performed using 0.5 unit of SAP (New 
England Biolabs) per 1 µg DNA at 37°C for one hour. Fifty to 100 ng of each restricted insert 
and plasmid (insert to plasmid ratio is ≥ 3:1) were ligated using T4 DNA ligase (Roche) at 15-
25°C for 15 min. 
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2.2.8 Transformation and electroporation of E.coli cells 
 
Competent E.coli cells (DH5α strain; Invitrogen and XL10-Gold strain; Stratagene) were 
transformed with 20-50 ng of ligation products using heat-shock. These bacterial cells were 
used for routine cloning during construction or propagation of plasmids. For the construction 
of large plasmids by homologous recombination (He et al., 1998), the electroporation 
competent RecA+ E.coli strain (BJ5183 strain; Stratagene) was used. Briefly, 1 µg of 
linearized and dephosphorylated transfer shuttle plasmid and a 100 ng of supercoiled acceptor 
plasmid (plasmid containing the Ad5 genome) were mixed with competent BJ5183 cells on 
ice and then subjected to electroporation using the Cell-Electroporator E.coli system (Gibco- 
Invitrogen). The electroporation parameters were set at 400 Volt, 330 µF, low-charge, low Ω 
and voltage booster at 4 kΩ. 
 
Transformed or electroporated cells were grown for one hour in LB broth at 37°C while 
shaking at 225rpm. Then a 100-250 µl of bacterial culture were plated on LB-agar containing 
ampicillin or gentamicin depending on the type of the antibiotic resistance gene in the 
plasmid used. LB-agar plates were incubated for 14-16 hours. Clones were picked and 
cultured in LB 
broth. After propagation of bacteria, plasmids were isolated by mini-preparation. Because the 
BJ5183 strain is unstable and its plasmid yield is very low, selected clones from this strain 
were transformed in XL10-Gold cells (suited for propagation of large plasmids) for further 
analysis and propagation of the plasmid. 
 
2.2.9 Construction of factor VIII expression plasmids with various truncated B- domain 
regions 
 
The pMT2-FVIII plasmid (Srour et al., 2008) containing the full-length factor VIII cDNA (nt 
# 1111 to 8386) was used as starting material (figure 6). First, the pMT2-FVIII plasmid was 
cut with ApaI (cuts at 4411 and 7302) and SpeI (cuts at 1695) and the large fragment (7548 
bp) representing the plasmid backbone and the rest of FVIII cDNA was gel extracted (Fig. 7, 
step 1). Then a Pwo-PCR fragment was created by two round PCR using the pMT2-FVIII as a 
template, first using the primer pair pMTF8-6085Ns / pMTF8-7310Aa that includes an NruI 
restriction site at the 5'-end and second, using the primers pMT2F8-6068SNS / pMTF8- 
7310Aa which adds an SpeI restriction site 5' to the NruI site (Fig. 7, step 2). The PCR 
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product was then cut with SpeI and ApaI, gel extracted and cloned into plasmid pMT2-FVIII 
which was cut with SpeI /ApaI (large fragment) to generate pMT2-F8-SNA plasmid (8808 
bp) (Fig. 7, step 3). Cloning was verified by DNA sequencing and digestion with SalI (gives 
two fragments one represents FVIII cDNA (~3 Kb in pMT2-F8-SNA) and one represents the 
pMT2 plasmid (~5.8 Kb)). 
 
 
Figure 6: Schematic representation of pMT2-FVIII expression plasmid containing the full length FVIII cDNA 
(7056 bp plus 214 bp of 3’UTR; GeneBank accession # M14113; nts # 172-7227 + 3’UTR nts # 7228-7440). 
 
The pMT2-F8-SNA plasmid was then cut with SpeI and NruI and the large fragment (~8790 
bp) was gel extracted (Fig. 7, step 4). Fragments (AàE) containing various lengths of the B- 
domain region were then amplified (Fig. 7, step 5) using the pMT2-FVIII plasmid as a 
template by Pwo-PCR or LD-PCR according to table 6 where the antisense primers hold an 
NruI restriction site. The amplified fragments were then cut with SpeI and NruI (Fig. 7, step 
6), gel extracted and cloned separately into plasmid pMT2-F8-SNA which has been cut with 
SpeI / NruI to generate the plasmids pMT2-F8-BDD (aa 743/1634), pMT2-F8-101 (aa 
844/1634), pMT2-F8-202 (aa 945/1634), pMT2-F8-292 (aa 1043/1634) and pMT2-F8-394 
(aa 1137/1634) (see table 7). The plasmids were then verified by DNA sequencing and Sal I 
digestion. 
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Figure 7: Schematic representation of the construction of various expression plasmids containing different 
lengths of the B domain. Steps 1,2 and 5 were performed using the pMT2-FVIII vector containing the full length 
FVIII cDNA (nts # 1111 to 8386). The B domain spans nts # 3388 to 6112 (aa 740 to 1648). 
 
 
 
 
Table 7: Different amplified fragments and the corresponding end plasmids. 
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Product Primer pair Product size 
End plasmid 
Size 
End plasmid 
name 
A 
pMTF8-1689s / 
pMTF8-3369Na 
~1694 bp 
10485 bp 
(BDD) 
pMT2-F8-BDD 
B 
pMTF8-1689s / 
pMTF8-3671Na 
~2000 bp 
10788 bp 
(101 aa/B) 
pMT2-F8-101 
C 
pMTF8-1689s / 
pMTF8-3973Na 
~2303 bp 
11091 bp 
(202 aa/B) 
pMT2-F8-202 
D 
pMTF8-1689s / 
pMTF8-4243Na 
~2573 bp 
11361 bp 
(292 aa/B) 
pMT2-F8-292 
E 
pMTF8-1689s / 
pMTF8-4551Na 
~2879 bp 
11667 bp 
(394 aa/B) 
pMT2-F8-394 
Table 7: Different amplified fragments and the corresponding end plasmids. 
 
 
2.2.10 Construction of recombinant bacmid DNA containing the adenovirus                
helper genome 
 
The plasmid pFastBac1 (Invitrogen) (Fig. 8 A) was used as a basic plasmid for the following 
cloning steps. The DNA fragments Ad5-L and Ad5-R (2707 bp; L corresponds to Ad5 nts 
4000 to 5781 plus Pme I & Eco RI restriction sites, while R corresponds to Ad5 nts 43935 to 
35832; GeneBank# NC_001406) were amplified by LD-PCR from pShuttle-CMV 
(Stratagene) using the primer pairs Ad5-4000Bgs / Ad5-3832Bga, cut with Bg1II, gel 
extracted and cloned between the AAV2 ITRs of plasmid pTRUF5 (obtained from Prof. 
Kleinschmidt, Heidelberg University; the plasmid contains the AAV2 5'- and 3'-ITRs 
corresponding to nts 1 to 145 & 4530 to 4675, respectively on AAV2 genome; GeneBank # 
AF043303) which was cut before with Bg1II and gel extracted to generate pTRUF5-Ad5LR. 
The fragment AAV2-5'ITR/Ad5LR/AAV2-3'ITR was cut from pTRUF5-Ad5LR with BspHI, 
blunt ended and cloned into pFastBac1, cut with NotI and blunt ended to generate the shuttle 
plasmid pBac-AAV2-Ad5LR (Fig. 8 B). 
 
The Ad5 genome was then cloned from pAdEasy-1 (Stratagene; Fig. 8 C) into the shuttle 
plasmid pBac-AAV2-Ad5LR (Fig. 8 B) by homologous recombination in bacterial cells 
(section 2.2.7). For this, the shuttle plasmid was linearized with PmeI (cuts between the two 
Ad5 homologous sequences), purified by phenol/chloroform purification and 
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2.2.10 Construction of recombinant bacmid DNA containing the adenovirus helper 
genome 
 
The plasmid pFastBac1 (Invitrogen) (Fig. 8 A) was used as a basic plasmid for the following 
cloning steps. The DNA fragments Ad5-L and Ad5-R (2707 bp; L corresponds to Ad5 nts 
4000 to 5781 plus Pme I & Eco RI restriction sites, while R corresponds to Ad5 nts 43935 to 
35832; GeneBank# NC_001406) were amplified by LD-PCR from pShuttle-CMV 
(Stratagene) using the primer pairs Ad5-4000Bgs / Ad5-3832Bga, cut with Bg1II, gel 
extracted and cloned between the AAV2 ITRs of plasmid pTRUF5 (obtained from Prof. 
Kleinschmidt, Heidelberg University; the plasmid contains the AAV2 5'- and 3'-ITRs 
corresponding to nts 1 to 145 & 4530 to 4675, respectively on AAV2 genome; GeneBank # 
AF043303) which was cut before with Bg1II and gel extracted to generate pTRUF5-Ad5LR. 
The fragment AAV2-5'ITR/Ad5LR/AAV2-3'ITR was cut from pTRUF5-Ad5LR with BspHI, 
blunt ended and cloned into pFastBac1, cut with NotI and blunt ended to generate the shuttle 
plasmid pBac-AAV2-Ad5LR (Fig. 8 B). 
 
The Ad5 genome was then cloned from pAdEasy-1 (Stratagene; Fig. 8 C) into the shuttle 
plasmid pBac-AAV2-Ad5LR (Fig. 8 B) by homologous recombination in bacterial cells 
(section 2.2.7). For this, the shuttle plasmid was linearized with PmeI (cuts between the two 
Ad5 homologous sequences), purified by phenol/chloroform purification and 
dephosphorylated with SAP. One µg linearized plasmid was mixed with 100 ng pAdEasy-1 
and added to 40 µl of BJ8153 electro competent bacterial cells. The DNA-bacteria mixture 
was then transferred into a 0.15 cm gap cuvette and electroporated to generate the plasmid 
pBac-AAV2-Ad5 (35,824 bp) containing the Ad5 genome (Fig. 8 D). The pBac-AAV2-Ad5 
selected clones were verified by DNA sequencing using the primers Ad5-4231a (covers the 
5'-ITR region and confirms the presence of the 5’ end of the Ad5 genome) and Ad5-35687s 
(covers the 3'-ITR region and confirms the presence of the 3’ end of the Ad5 genome), by 
Taq-PCR using the primers Ad5-4000xs / Ad5-7000a (confirms the presence of part of the 
Ad5 genome which reflect an intact construct) and by digestion with SmaI (gives the 
following fragments: 6447, 11, 195 [5'-ITR], 2463, 6480, 1398, 4456, 1455, 3540, 3386, 230, 
652, 2278, 2262, 550 [3'-ITR] and 11 bp). 
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Figure 8: Construction of the pBac-AAV2-Ad5. 
 
 
 
To support the AAV-ITRs replication in trans, a Rep-protein is needed. For this, The MMTV- 
LTR promoter (757 bp; nts 591 to 1347 on MMTV genome; GeneBank#V01175) was 
amplified from pDG plasmid using primers MMTV-591Bsps / MMTV-1347Bama and cloned 
at BspE1 / BamHI sites in pFastBac1 plasmid to generate pBac-MMTV (~5387 bp; digestion 
of pFastBac1 with BspE1 / BamHI removes the insect PH promoter). The bGH polyA signal 
(258 bp; most of it matches nt# 75 to 299 according to GeneBank # AF117346) plus 126 bp 
from the 5' end of ß-globin polyA were amplified from pTRE2-Luc-Ad5 (Clontech) using 
primers BGH-2532NMBs / BGH-2916EcoRa and cloned into BamHI / EcoRI sites of 
pFastBac1-MMTV to generate pBac-MMTV-bGH (~5780). pBac-AAV2-Rep (~7802 bp) 
was then constructed by amplifying the AAV2-Rep genes (2022 bp; nt 289 to 2310; 
GeneBank# AF043303) from pDG plasmid using primers AAV2-289MLs / AAV2-2310NHa 
and cloning them at MluI / NheI sites in pBac-MMTV-bGH (Fig. 9). 
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Figure 9: Schematic representation of pBac-AAV2-Rep and pBac-EGFP. 
 
Expression of the AAV2-Rep gene was tested in both Sf9 and 293T cells. SF9 cells were 
transfected with plasmid pBac-AAV2-Rep using Cellfectin reagent, incubated for 48 hours 
and then used for total RNA preparation using Trizol reagent (see section 2.2.2). 293T cells 
were transfected with pBac-AAV2-Rep and pDG (contains the Rep gene expression cassette 
that were used for pBac-AAV2-Rep cloning) plasmids using Lipofectamin 2000, incubated 
for 48 hours and then used for total RNA preparation using Trizol reagent. Total RNA was 
subject to RT PCR using Superscript III reverse transcriptase followed by Taq-PCR using the 
primer pairs AAV2-2310a / AAV2-1380s (which give a product of 1 kb) and AAV2-2310a / 
AAV2-321s (which give a PCR product of 2 kb). 
 
As a positive control for transfecting insect cells, the plasmid pBac-EGFP was constructed 
(Fig. 9). The CMV-EGFP was amplified from pEGFP-C1 using the primer pair CMV- 
1Ecos/GFP-1329Ha. The resulting amplification product was digested with EcoRI/HindIII 
and cloned in EcoRI/HindIII digested pFastBac1. 
 
Recombinant bacmids were constructed by site-specific transposition in DH10Bac bacterial 
cells [contains the baculovirus shuttle vector (bacmid) bMON14272 (136 kb); Invitrogen] 
(Fig. 10). Twenty five µl of DH10Bac were mixed with 0.25 ng of shuttle plasmid pBac- 
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Cells were heat shocked at 42°C for 45 seconds, incubated on ice for 2 min and a 250 µl SOC 
medium was then added to them. Transformed cells were incubated 4 hours at 37°C while 
shaking at 225 rpm and then diluted 1:10 and 1:100 with SOC medium. One hundred µl of 
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colony from each plate were picked and cultured in 2.5 ml LB broth containing the three 
antibiotics and incubated at 37°C overnight. 
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of pFastBac1 with BspE1 / BamHI removes the insect PH promoter). The bGH polyA signal 
(258 bp; most of it matches nt# 75 to 299 according to GeneBank # AF117346) plus 126 bp 
from the 5' end of ß-globin polyA were amplified from pTRE2-Luc-Ad5 (Clontech) using 
primers BGH-2532NMBs / BGH-2916EcoRa and cloned into BamHI / EcoRI sites of 
pFastBac1-MMTV to generate pBac-MMTV-bGH (~5780). pBac-AAV2-Rep (~7802 bp) 
was then constructed by amplifying the AAV2-Rep genes (2022 bp; nt 289 to 2310; 
GeneBank# AF043303) from pDG plasmid using primers AAV2-289MLs / AAV2-2310NHa 
and  cloning them at MluI / NheI sites in pBac-MMTV-bGH (Fig. 9). 
 
 
Figure 9: Schematic representation of pBac-AAV2-Rep and pBac-EGFP. 
 
Expression of the AAV2-Rep gene was tested in both Sf9 and 293T cells. SF9 cells were 
transfected with plasmid pBac-AAV2-Rep using Cellfectin reagent, incubated for 48 hours 
and then used for total RN  preparation using Trizol reagent (see section 2.2.2). 293T cells 
were transfected with pBac-AAV2-Rep and pDG (contains the Rep gene expression cassette 
that were used for pBac-AAV2-Rep cloning) plasmids using Lipofectamin 2000, incubated 
for 48 hours and then used for total RNA preparation using Trizol reagent. Total RNA was 
subject to RT PCR using Superscript III reverse transcriptase followed by Taq-PCR using the 
primer pairs AAV2-2310a / AAV2-1380s (which give a product of 1 kb) and AAV2-2310a / 
AAV2-321s (which give a PCR product of 2 kb). 
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(Fig. 9). The CMV-EGFP was amplified from pEGFP-C1 using the primer pair CMV-
1Ecos/GFP-1329Ha. The resulting amplification product was digested with EcoRI/HindIII 
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Figure 10: Generation of recombinant bacmid DNA “bBac-AAV2-Ad5”. 
 
Recombinant bacmid DNA (bBac-AAV2-Ad5; bBac-EGFP; bBac-AAV2-Rep) was isolated 
according to section 2.2.1. Recombinant bacmid (bBac-AAV2-Ad5) was analyzed by Taq- 
PCR using M13 forward / M13 reverse primers (confirms the presence of the plasmid insert: 
an empty bacmid gives a ~270 bp PCR product, a transposed bacmid gives no product as Taq 
polymerase cannot amplify such large insert >35 kb), M13 forward /Ad5-4231a primers 
(covers the 5'-ITR region, confirms the presence of the 5’end of the Ad5 genome and gives 
~3.1 kb PCR product), M13 reverse / Ad5-35687s primers (covers the 3'-ITR region, 
confirms the presence of the 3’end of the Ad5 genome and gives ~1.55 kb PCR product) and 
Ad5- 4000xs / Ad5-7000a primers (confirms the presence of Ad5 genome and gives ~3.0 kb 
PCR product). bBac-EGFP was characterized by Taq PCR using the M13 forward and M13 
reverse primers. The presence of the EGFP gene resulted in a 3.6 kb fragment. 
 
bBac-AAV2-Rep was analyzed by Taq-PCR using M13 forward / M13 reverse primer pair 
(confirms the presence of the plasmid insert: an empty bacmid gives a ~270 bp PCR product, 
a transposed bacmid gives a ~5.3 kb PCR product), M13 forward / MMTV-1347a primers 
(covers the 5’ AAV2-Rep construct end and gives a ~2.3 kb PCR product) and AAV2-321s / 
M13 reverse primers (covers the 3’ AAV2-Rep construct end and gives a ~2.8 kb PCR 
product). 
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Recombinant bacmid DNA (bBac-AAV2-Ad5; bBac-EGFP; bBac-AAV2-Rep) was isolated 
according to section 2.2.1. Recombinant bacmid (bBac-AAV2-Ad5) was analyzed by Taq-
PCR using M13 forward / M13 reverse primers (confirms the presence of the plasmid insert: 
an empty bacmid gives a ~270 bp PCR product, a transposed bacmid gives no product as Taq 
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2.3 Cell culture 
 
2.3.1 Cultivation and storage of cells 
 
Cell lines (HEK 293T, COS-1 and CHO-DHFR[-]) were grown in their respective media 
(section II.1.4) supplied with 10% fetal bovine serum (FBS), 100 U/ml of Penicillin-G and 
100 µg/ml of Streptomycin, and 5% CO2 at 37°C (Freshney, 2000). 
 
Cells were grown in different tissue culture dishes or plates (Nunc) of different sizes 
depending on the type of the experiment. For cell expansion, cells were washed with 
Dulbecco's-PBS, trypsinized with Trypsin-EDTA (Invitrogen) and seeded at the appropriate 
ratio in new dishes. Stocks of cell lines were prepared in freezing medium (70% culture 
medium, 20% FBS and 10% DMSO) and maintained in liquid nitrogen (Freshney, 2000). 
 
2.3.2 Transient expression of B-domain deleted constructs in mammalian cell lines 
 
2.3.2.1 Transfection 
 
Transfection of expression plasmids in the three animal cell lines was performed on liposomal 
basis using the transfection reagent Lipofectamine 2000 (Invitrogen) according to the 
instructions of the supplier. Transient transfections were done in 6-well plates with cells 
grown to ~90% confluence in an antibiotic free medium. First, 4 µg of each expression 
plasmid was diluted in 250 µl Opti-MEM I (reduced serum medium; Invitrogen) while a 10 µl 
Lipofectamine 2000 (1 mg/ml) was diluted in 250 µl Opti-MEM I, separately. After 5 min 
incubation at RT, both mixtures were combined, mixed gently and incubated 20 min at RT. 
500 µl of DNA-Lipofectamine 2000 complexes were then added to the respective well 
containing cells and medium and mixed gently by rocking the plate back and forth. The plate 
was then incubated at 37°C and 5% CO2 for 4 hours. Then the medium was replaced by the 
respective normal medium. The efficiency of transfection was controlled by the transfection 
of an eGFP expression plasmid pEGFP-C1. 
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2.3.2.2 Expression studies 
 
Expression experiments were done in three mammalian cell lines: HEK 293, COS-7 and 
CHO-DHFR[-]. One day before each expression experiment, 1 * 106 cells in 2 ml growth 
medium were plated per well so that they reached ~90% confluency at the time of 
transfection. The cell culture media used were without phenol red as it interferes with FVIII 
activity measurement. Expression experiments were performed using the five plasmids 
containing the B-domain deleted constructs along with pMT2-FVIII (contains the full length 
factor VIII cDNA) and pMT2-FVIII-BDD (Bonn-BDD; codes for a truncated factor VIII 
protein in which amino acid 852 is joined to amino acid 1524; Srour et al., 2008; Fig. 11). All 
the expression experiments were performed using the same DNA and Lipofectamine 2000 
quantities. Twenty-four hours after transfection, growth medium was replaced with a fresh 
medium, collected 24 hours later (48 hours after transfection), and then again a fresh medium 
was added and collected 24 hours later (72 hours after transfection). The two medium 
collections were centrifuged at 700 x g at 4°C for 5 min, aliquoted and stored at -80°C. 
 
 
Figure 11: Schematic representation of pMT2-FVIII-BDD (BONN-BDD) expression plasmid containing the 
FVIII-B domain deleted (FVIII-BDD) cDNA, which is the same as FVIII full length except that most of the B- 
domain is deleted from nts 2795 to 4804 (nucleotides order is according to Gene Bank # M14113). 
 
Aliquots were used to measure factor VIII activity using the clotting and the chromogenic 
assays (section 2.4.2). Factor VIII antigen (in culture medium) was quantified by ELISA 
(section 2.4.3) for the cell line that showed the highest factor VIII activity. The specific factor 
VIII activity was then calculated. In each expression experiment, the expression plasmids 
were transfected in triplicates (3 wells for each expression plasmid) along with two negative 
control wells (no DNA) and one positive control well (pEGFP-C1). 
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domain is deleted from nts 2795 to 4804 (nucleotides order is according to Gene Bank # M14113). 
 
Aliquots were used to measure factor VIII activity using the clotting and the chromogenic 
assays (section 2.4.2). Factor VIII antigen (in culture medium) was quantified by ELISA 
(section 2.4.3) for the cell line that showed the highest factor VIII activity. The specific factor 
VIII activity was then calculated. In each expression experiment, the expression plasmids 
were transfec ed in triplic tes (3 wells for each expression plasmid) along with two egative 
control wells (no DNA) and one positive control well (pEGFP-C1).  
 
2.3.3 Generation of stable cell lines expressing various factor VIII protein                   
variants in CHO-DHFR[-] cells 
 
2.3.3.1 Transfection, selection and amplification of CHO-DHFR[-] 
 
Transfection. 20 !g of ethanol precipitated linearized (cut with MluI) DNA of each 
expression plasmid (pMT2-F8-BDD, pMT2-F8-202, pMT2-F8-394 and pMT2-FVIII) and 50 
!l Lipofectamine 2000 was used to transfect CHO-DHFR[-] cells which were grown in 
IMDM (containing hypoxanthine thymidin reagent; Invitrogen) to 90% confluence in 10 cm ø 
dishes. DNA-Lipofectamine complexes were incubated with the cells for 4 hours. Growth 
medium containing the complexes was then removed and 3 ml of 10% glycerin were added to 
the cells for 2 min to facilitate the DNA uptake by cells (Sambrook and Russell, 2001). Cells 
were then washed by PBS and 10 ml of fresh growth medium was added. 
 
	   53	  
2.3.3 Generation of stable cell lines expressing various factor VIII protein variants in 
CHO-DHFR[-] cells 
 
2.3.3.1 Transfection, selection and amplification of CHO-DHFR[-] 
 
Transfection. 20 µg of ethanol precipitated linearized (cut with MluI) DNA of each 
expression plasmid (pMT2-F8-BDD, pMT2-F8-202, pMT2-F8-394 and pMT2-FVIII) and 50 
µl Lipofectamine 2000 was used to transfect CHO-DHFR[-] cells which were grown in 
IMDM (containing hypoxanthine thymidin reagent; Invitrogen) to 90% confluence in 10 cm ø 
dishes. DNA-Lipofectamine complexes were incubated with the cells for 4 hours. Growth 
medium containing the complexes was then removed and 3 ml of 10% glycerin were added to 
the cells for 2 min to facilitate the DNA uptake by cells (Sambrook and Russell, 2001). Cells 
were then washed by PBS and 10 ml of fresh growth medium was added. 
 
Selection. After 48 hours, transfected cells were splitted into five 10 cm ø dishes at 1:15 ratio 
using a 10 ml selection medium (IMDM containing dialyzed FBS [Sigma] and deficient in 
hypoxanthine and thymidin). To each dish a different Methotrexate (MTX; a selection and 
amplification agent; Sigma) quantity was added (20 nM, 50 nM, 100 nM, 200 nM and 400 
nM). The selection medium did not contain nucleosides so that only cells that have the 
expression plasmid (containing the DHFR gene) could grow. The selection medium and the 
respective MTX quantity was changed every two days until a well-defined new colonies 
appear (2-3 weeks). Colonies were then pooled and tested for productivity by assaying factor 
VIII activity in culture medium. Productive dishes were passaged (splitted and let grow) 4 
times and the productivity was assessed each time. Dishes that kept the productivity over 
passaging were expanded to several dishes for storage, amplification and cloning. 
 
 
Amplification. Productive dishes were amplified by splitting the cells in a higher MTX 
concentration steps (5x, 10x, 20x and 50x for example). In each new MTX concentration step 
the cells were maintained until confluency, passaged 4 times and then the productivity was 
assessed. Cells that showed higher productivity were expanded for storage, cloning and a 
further amplification step. 
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2.3.3.2 Limited dilution cloning and sub cloning 
 
Productive pooled clones were cloned by serial dilution in 96 well plates (Corning protocol, 
MA, USA) (Fig. 12). Cells were trypsinized and 2 * 104 cells/ml cell suspension was 
prepared. In a 96 well plate, a 100 µl selective medium was added in all wells except well A1 
(see diagram below), then 200 µl of the cell suspension was added to well A1. Using a single 
channel pipettor, 100 µl were quickly transferred from A1 to B1 and mixed by gently 
pipetting. Using the same tip, this 1:2 dilution was repeated down the entire column, ending 
by discarding 100 µl from H1. Using an 8-channel micropipettor, 100 µl additional medium 
was added to each well in column 1, mixed by gentle pipetting and then 100 µl was 
transferred quickly from column 1 (A1 through H1) to column 2 (A2 through H2). Using the 
same tips, these 1:2 dilutions were repeated across the entire plate, discarding 100 µl from 
each of the wells of the last column (A12 through H12) so that all the wells ended up with 
100 µl of cell suspension. The final volume in all wells was then brought to 200 µl by adding 
100 µl medium to each well. Cells were allowed to settle down at 37°C for one hour and wells 
were then checked for the presence of single cells using an inverted microscope. Wells 
containing single cells were marked and followed until they had formed detectable clones 
(approximately 2 weeks incubation at 37°C in a CO2 incubator). Single colonies were then 
sub-cultured into a larger vessel (24-well plate) and the productivity (FVIII activity) was then 
assessed upon confluency. Highly productive clones were then propagated into 6-well plates 
followed by 10 cm ø dishes for storage, amplification and sub-cloning. Sub-cloning increases 
the likelihood that the cells originated from a single cell and possibly gives higher productive 
clones. It was performed using the cloning protocol. 
 
Figure 12: Schematic representation of serial dilutions in 96-well plate.  
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2.3.4 Generation of helper recombinant baculovirus in insect cells were performed 
according to the Bac-to-Bac Baculovirus Expression System manual instructions (Invitrogen). 
 
2.3.4.1 Transfection of Sf9 cells 
 
Insect cells (Sf9 cell line, ATCC # CRL-1711) were grown in supplemented Grace's Insect 
Cell Culture Medium (Invitrogen) at 27°C supplied with 10% Insect Cell Culture Tested FBS 
(Sigma), 50 U/ml penicillin and 50 !g/ml streptomycin. Sf9 cells were seeded at 9*105 cells 
per well in a 6-well plate and allowed to attach at 27°C for one hour prior to transfection. For 
each transfection sample, 1 !g of purified bacmid DNA (section II.2.1) were diluted in 100 !l 
of unsupplemented Grace's medium (Invitrogen), and a 6 !l well mixed Cellfectin reagent 
(Invitrogen) were diluted in a 100 !l unsupplemented Grace's medium, separately. Both 
mixtures were then combined, mixed gently and incubated at RT for 15 to 45 min. During this 
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2.3.4 Generation of helper recombinant baculovirus in insect cells:  were performed 
according to the Bac-to-Bac Baculovirus Expression System manual instructions (Invitrogen). 
 
2.3.4.1 Transfection of Sf9 cells 
 
Insect cells (Sf9 cell line, ATCC # CRL-1711) were grown in supplemented Grace's Insect 
Cell Culture Medium (Invitrogen) at 27°C supplied with 10% Insect Cell Culture Tested FBS 
(Sigma), 50 U/ml penicillin and 50 µg/ml streptomycin. Sf9 cells were seeded at 9*105 cells 
per well in a 6-well plate and allowed to attach at 27°C for one hour prior to transfection. For 
each transfection sample, 1 µg of purified bacmid DNA (section II.2.1) were diluted in 100 µl 
of unsupplemented Grace's medium (Invitrogen), and a 6 µl well mixed Cellfectin reagent 
(Invitrogen) were diluted in a 100 µl unsupplemented Grace's medium, separately. Both 
mixtures were then combined, mixed gently and incubated at RT for 15 to 45 min. During this 
incubation time, media was removed from cells and washed once with 2 ml unsupplemented 
Grace's medium. To each DNA: lipid complex, 0.8 ml unsupplemented Grace's medium was 
added, mixed gently and the complexes were added then to each well containing the cells. 
After 5 hours incubation at 27°C, DNA: lipid complexes were removed and a 2 ml 
supplemented Grace's medium was added to the cells (Fig. 13). 
 
Figure 13: Production of recombinant Baculovirus particles “Bac-AAV2-Ad5”. 
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incubation time, media was removed from cells and washed once with 2 ml unsupplemented 
Grace's medium. To each DNA: lipid complex, 0.8 ml unsupplemented Grace's medium was 
added, mixed gently and the complexes were added then to each well containing the cells. 
After 5 hours incubation at 27°C, DNA: lipid complexes were removed and a 2 ml 
supplemented Grace's medium was added to the cells (Fig. 13). 
 
Figure 13: Production of recombinant Baculovirus particles “Bac-AAV2-Ad5”. 
 
Budded viruses should be released into the medium 72 hours after transfection. Virally-
infected insect cells typically show the following characteristics: Increased cell diameter and 
size of cell nuclei (first 24 hours), cessation of cell growth, granular appearance as a sign of 
viral budding, detachment (24-72 hours) and cell lysis (>72 hours). Once the cells appear 
infected, the virus was harvested from cell culture medium by collecting the medium in a 
sterile 15 ml snap-cap tube, and subsequent centrifugation at 500 xg for 5 min. The clarified 
supernatant containing the virus was then transferred into a fresh snap-cap tube and labeled as 
the P1 viral stock. 
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Budded viruses should be released into the medium 72 hours after transfection. Virally- 
infected insect cells typically show the following characteristics: Increased cell diameter and 
size of cell nuclei (first 24 hours), cessation of cell growth, granular appearance as a sign of 
viral budding, detachment (24-72 hours) and cell lysis (>72 hours). Once the cells appear 
infected, the virus was harvested from cell culture medium by collecting the medium in a 
sterile 15 ml snap-cap tube, and subsequent centrifugation at 500 xg for 5 min. The clarified 
supernatant containing the virus was then transferred into a fresh snap-cap tube and labeled as 
the P1 viral stock. 
 
2.3.4.2 Amplification of P1 viral stock 
 
The P1 viral stock is a small-scale, low-titer stock (generally ranges from 1*106 to 1*107 
plaque forming units (pfu)/ml). Amplification of P1 allows the production of a P2 viral stock 
with a titer ranging from 1*107 to 1*108 pfu/ml. To amplify the P1 viral stock, cells 
(2*106/well in 6-well plate) were infected at a multiplicity of infection (MOI) ranging from 
0.05 to 0.1. MOI is defined as the number of virus particles per cell. 
 
 
 
To calculate how much viral stock must be added to obtain a specific MOI, the following 
formula was used: 
                                            MOI(pfu/ml) * number of cells 
Inoculum required (ml)= (.............................................) 
                                              Titer of viral stock (pfu/ml) 
 
Assuming a titer of 5*106 pfu/ml and 2*106 cells/well (2 ml culture) which has to be infected 
by an MOI of 0.1 then: 
                                    
                                           0.1 pfu/ml * 2 * 106 cells 
Inoculum required (ml)=........................................... = 0.04 ml 
                                                  5* 106 pfu/ml 
 
So, 0.04 ml of P1 viral stock was used to infect Sf9 cells (seeded one hour before infection in 
6-well plates at 2*106 cells /well). Forty eight hours post-infection, medium containing virus 
was collected in 15 ml snap-cap tubes, centrifuged at 500 xg for 5 min, and then the 
supernatant was transferred to a fresh tube labeled P2 viral stock. 
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2.3.4.3 Plaque assay 
 
To determine the titer of the baculoviral stock and to plaque purify the virus, plaque assay 
was performed. The clarified baculoviral stock P2 was diluted in supplemented Grace's Insect 
Medium without FBS to an 8-log serial dilution (10-1 to 10-8). Sf9 cells were seeded into 6- 
well plates at 1 * 106 cells /well, allowed to settle at RT for 1.0 hour and then checked using 
an inverted microscope for attachment and for 50% confluence. Medium was then removed 
and 1.0 ml of each viral dilution (10-3 to 10-8) was added to the cells and incubated at RT for 
1.0 hour. The medium containing the virus was then removed starting from the highest 
dilution to the lowest. Then a 2 ml plaquing medium (Supplemented Grace's Insect Medium 
containing 10% FBS and 2% agarose; Invitrogen) was added to the cells, and the agarose 
overlaying the cells was allowed to harden at RT for 20 min. Now, cells were incubated in a 
27°C humidified incubator for 7-10 days until plaques were visible and ready to count. The 
titer of the viral stock was then calculated according to the following formula: 
                                                                                                      1 
Titer (pfu/ml) = number of plaques * dilution factor * ................................... 
                                                                                          ml of inoculum / well 
 
 
 
 
 
2.3.4.4 Virus preparation 
 
A viral stock from a single viral clone was generated by plaque purifying the baculovirus. For 
this, Sf9 cells were seeded into 6-well plate at 1 * 106 cells /well and let be settled at RT for 
1.0 hour. Using a sterile Pasteur pipette and bulb, a clear plaque was picked and the agarose 
plug (containing the virus) was transferred into a 1.5 ml microcentrifuge tube containing 500 
µl supplemented Grace's medium, and then mixed well by vortexing. 100 µl of the agarose 
plug solution was then added to each well. Cells were incubated in a 27°C humidified 
incubator for 72 hours. Medium containing the virus was then collected in a sterile 15 ml 
snap-cap tubes, centrifuged at 500 x g for 5 min and clarified supernatant (the plaque-purified 
viral stock) was then transferred to fresh snap-cap tubes. This viral stock was then amplified 
according to section 2.3.4.2. 
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2.3.4.5 Verifying the purified virus by PCR analysis 
 
Purified viral DNA was extracted from viral stock using the extra chromosomal DNA 
isolation protocol (section 2.2.1). Viral DNA (vBac-AAV2-Ad5 and vBac-AAV2-Rep) was 
verified by Taq-PCR using the same approach followed in verifying Bacmid DNA (section 
2.2.10). 
 
2.3.5 Rescuing the helper dependant adenovirus in HEK 293T cells (Figure 14) 
 
The ability of the baculovirus to infect HEK 293 cells were tested by infecting 90 % confluent 
cultures with 200 µl vBac-EGFP P2 viral stock in 6-well plates once at 37 °C for one hour 
and once at 28 °C for 4 hours. 
 
To rescue the helper dependant adenovirus in HEK 293 cells, cells were splitted into 6-well 
plates (8 wells total) one day before transfection at 1 * 106 cells/well. On 90% confluence, 
cells were transfected (section 2.3.2.1) with PmeI linearized mini-Ad5 helper dependent 
vector (pAd5-AAT-hf8) (6 wells) by lipofection along with a negative control well (no DNA) 
and a positive control (of transfection) well (pBac-EGFP). One day after transfection, HEK 
293 cells were infected with different concentrations of Bac-AAV2-Ad5 particles (using 
different MOI) in combination with vBac-AAV2-Rep according to table 8 with the last well 
(well#8) infected with vBac-AAV2-Rep only as a negative control for the helper dependent 
adenovirus production. 
 
Table 8: Infection mixtures used to rescue the helper dependent adenovirus in HEK 293 cells. 
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and a positive control (of transf ction) well (pBac-EGFP). One day after tr nsfection, HEK 
293 cells were infected with different concentrations of Bac-AAV2-Ad5 particles (using 
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Well#1: 
Negative control 
 
Well#3: 
vBac-AAV2-Ad5 
Plaque 9 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#5: 
vBac-AAV2-Ad5 
Plaque 16 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#7: 
vBac-AAV2-Ad5 
Plaque 5 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#2: 
Positive control 
(pBac-EGFP) 
Well#4: 
vBac-AAV2-Ad5 
Plaque 9 at 500 MOI 
+ 
vBac-AAV2-Rep 
Plaque 1 at 200 MOI 
Well#6: 
vBac-AAV2-Ad5 
Plaque 16 at 500 MOI 
+ 
vBac-AAV2-Rep 
Plaque 1 at 200 MOI 
Well#8: 
vBac-AAV2-Rep 
Plaque at 200 MOI 
Table 8: Infection mixtures used to rescue the helper dependent adenovirus in HEK 293 cells. 
 
 
Figure 14: Rescuing the helper dependant adenovirus in HEK 293 cells. 
 
The detailed infection protocol of HEK 293 cells was according to Kenoutis et al. 2006. For 
this, HEK 293 cells were washed with D-PBS and the viral mixtures prepared in 0.5 ml D-
PBS were added to each corresponding well. After 4-6 hours incubation at 28 °C, mixtures 
were removed and 2 ml complete medium (DMEM) were added. Cytopathic effects and signs 
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Figure 14: Rescuing the helper dependant adenovirus in HEK 293 cells. 
 
The detailed infection protocol of HEK 293 cells was according to Kenoutis et al. 2006. For 
this, HEK 293 cells were washed with D-PBS and the viral mixtures prepared in 0.5 ml D- 
PBS were added to each corresponding well. After 4-6 hours incubation at 28 °C, mixtures 
were removed and 2 ml complete medium (DMEM) were added. Cytopathic effects and signs 
of viral production were followed over five days. Culture medium was collected from 
corresponding wells and used for FVIII: Ag ELISA after 10x concentration. Cells were 
trypsinized and lysed in PBS by 4 rounds of freeze /thaw cycles (freezing for 5 min in dry ice 
/ ethanol bath and thawing at 37°C). Lysates (200 µl) were used for extra chromosomal DNA 
isolation and /or used for a second round of infection in which fresh (new) 90% confluent 
HEK 293 cells in 6-well plates were infected with 200 µl lysates at 37°C for 45 min after 
being infected with the Helper vector for one hour at RT. Signs of viral production were 
followed over 4 days. Cells were then freezed and thawed as mentioned above and lysates 
were used for extra chromosomal DNA isolation (section 2.2.1) and for a third round of 
infection using the same protocol mentioned above for the second round of infection. 
 
FVIII: Ag was assessed in medium and extra chromosomal DNA was digested by DpnI to test 
whether it is the original transfected DNA or a newly produced DNA in HEK 293 cells, 
which was under the support of our designed hybrid helper vector. 
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cells were transfected (section 2.3.2.1) with PmeI linearized mini-Ad5 helper dependent 
vector (pAd5-AAT-hf8) (6 wells) by lipofection along with a negative control well (no DNA) 
and a positive control (of transfection) well (pBac-EGFP). One day after transfection, HEK 
293 cells were infected with different concentrations of Bac-AAV2-Ad5 particles (using 
different MOI) in combination with vBac-AAV2-Rep according to table 8 with the last well 
(well#8) infected with vBac-AAV2-Rep only as a negative control for the helper dependent 
adenovirus production.  
 
Well#1: 
Negative control 
 
Well#3: 
vBac-AAV2-Ad5 
Plaque 9 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#5: 
vBac-AAV2-Ad5 
Plaque 16 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#7: 
vBac-AAV2-Ad5 
Plaque 5 at 2000 MOI 
+ 
vBac-Rep Plaque 1 
at 200 MOI 
Well#2: 
Positive control 
(pBac-EGFP) 
Well#4: 
vBac-AAV2-Ad5 
Plaque 9 at 500 MOI 
+ 
vBac-AAV2-Rep 
Plaque 1 at 200 MOI 
Well#6: 
vBac-AAV2-Ad5 
Plaque 16 at 500 MOI 
+ 
vBac-AAV2-Rep 
Plaque 1 at 200 MOI 
Well#8: 
vBac-AAV2-Rep 
Plaque at 200 MOI 
Table 8: Infection mixtures used to rescue the helper dependent adenovirus in HEK 293 cells. 
 
 
Figure 14: Rescuing the helper dependant adenovirus in HEK 293 cells. 
 
The detailed infection pr t col of HEK 293 cells was according to Kenoutis et al. 2006. For 
this, HEK 293 cells were washed with D-PBS and the viral mixtures prepared in 0.5 ml D-
PBS w re ad ed to each corresponding well. After 4-6 hours incubation at 28 °C, mixtures 
w r  removed and 2 ml complete medium (DMEM) were ad ed. Cytopathic ffects and signs 
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2.4 Biochemical methods 
 
2.4.1 Purification of factor VIII protein expressed in culture medium 
 
FVIII containing medium (300 ml) collected from stable cell line cultures was concentrated 
10x using Vivaspin 20 columns (30,000 MWCO). Concentrated medium was then mixed with 
0.5 ml FVIII-Select beads (monoclonal anti-FVIII antibody beads) and shaken at 4°C for 2 
hours. Beads were then pelleted (2 min centrifugation at 2000 rpm), resuspended in buffer A, 
loaded onto a 2 ml pierce column and washed 4 times with buffer A (after each addition of 
buffer A, the column was centrifuged at 200 rpm for 2 min). FVIII was then eluted with 
buffer B and 8 batches were collected (beads were suspended 8 times with 0.5 ml buffer B 
and centrifuged for 5 min at 200 rpm, each time the eluate was collected in a new tube). 
Batches were assayed for FVIII activity and the productive batches were pooled and buffer 
exchanged on a PD-10 desalting columns with buffer A. Eluates were then concentrated using 
Amicon Ultracel (30K) filters and concentrates were then tested for FVIII-activity and FVIII- 
antigen. For activity assays (see section 2.4.2), purified FVIII was diluted in human FVIII- 
deficient plasma and for antigen quantitation (section 2.4.3); purified FVIII was diluted in 
buffer A. For testing the purity of the purified FVIII, approximately 1 U FVIII (measured by 
FVIII: Ag ELISA) were digested with human alpha thrombin and detected by western 
blotting (see section 2.4.4). 
 
2.4.2 Factor VIII activity assays 
 
FVIII activity (FVIII: C) was measured in conditioned medium using the clotting assay which 
is based on the measurement of activated Partial Thromboplastin Time (aPTT) and / or the 
chromogenic assay that is based on the activation of a chromogenic substrate. In both assays, 
conditioned medium was treated as a plasma sample. 
 
2.4.2.1 Clotting assay 
 
Clotting assays are based on the measurement of aPTT (Turi and Peerschke, 1986; Ray and 
Hawson, 1989; Van den Besselaar et al., 1993) using ACLTM-analysis systems 
(Instrumentation Laboratories) that work on centrifugational analyzer principle. Sample to be 
tested was mixed with FVIII-deficient plasma and then the intrinsic coagulation pathway was 
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activated by the addition of bovine cephaline and microcrystalline kieselguhr. Clot formation 
was initiated by adding Ca+2 and the machine starts to measure the change in light scattering. 
When the maximum scattering was attained, time (reflects aPTT measurement) was stopped. 
Time of measured samples was converted into % using a standard curve that the machine 
plots automatically from three standard plasma dilutions. A 100% value corresponds to the 
average FVIII: C in normal pooled plasma. Samples with activities higher than 100% were 
diluted. Samples with low activity values were evaluated by an additional standard curve for 
low values. ACLTM-analysis system was operated according the manufacturer specifications. 
The pipetting of reagents and samples was done automatically. In each measurement, standard 
plasma was included as a positive control and a conditioned medium from cells that do not 
secret FVIII was included as a negative control. 
 
2.4.2.2 Chromogenic assay 
 
In the chromogenic assay (van Dieijen et al., 1981), FVIII: C was measured by the generation 
of factor Xa using "Factor VIII Chromogenic assay" kit (Dade Behring, Marburg). In this 
assay, FVIII is activated by the addition of thrombin. Activated FVIII (FVIIIa) works as a 
cofactor with FIXa, Phospholipids and Ca+2 in the activation of FX to FXa. FXa activity is 
measured through the hydrolysis of FXa-specific p-nitroaniline substrate. The initial rate of 
release of p-nitroanaline measured spectrophotometrically at 405 nm is proportional to FXa 
activity that reflects FVIII: C in the sample. The assay was performed automatically on MLA 
Electra 900C coagulation analyzer. Samples were diluted 1:41 using 0.9% sodium chloride 
and results were calculated according to an automatically plotted standard curve. In each 
measurement, two control plasmas were run: Control Plasma N (normal range) and Control 
Plasma P (pathologic range). 
 
2.4.3 Factor VIII antigen assay 
 
FVIII antigen concentration (FVIII:Ag) was measured using FVIII:Ag-ELISA (Asserachrom 
VIII:Ag; Diagnostica Stago; Girma et al., 1998). Two monoclonal antibodies (mAb) directed 
against distinct epitopes of the human FVIII light chain have been used in this sandwich- 
ELISA. The first mAb was immobilized on wells of microtiter plates. FVIII-containing 
samples were incubated at 20°C for 2 hours. Following washing, the second antibody, 
coupled to peroxidase, was incubated at 20°C for 2 hours. Bound antibody was measured by 
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incubating with tetramethybenzidin for 5 minutes, blocking the reaction with 50 µl of 1 M 
H2SO4 and reading absorbance at 450 nm. Control plasma, containing 1 U/ml FVIII: C as 
estimated by comparing with the International standard, was used as a reference (100%). The 
ELISA was done according to the manufacturer recommendations. The standard curve was 
made by diluting the control plasma. The detection limit of this assay was 0.5% of FVIII. 
 
2.4.4 Purified factor VIII cleavage by thrombin and western blot analysis 
 
For western blot analysis of purified FVIII products (F8-BDD, F8-202, F8-394 and F8-Full), 
approximately 1 U containing aliqoutes (as measured by FVIII:Ag, section II.4.3) were mixed 
with Laemmli buffer, and heat denatured at 95°C for 5 min. For complete thrombin digestion, 
aliquotes containing 1 U FVIII were digested with 0.5 nM human alpha thrombin (FIIa) in 1x 
FIIa buffer at 37°C for 4 min. The reaction was then stopped by the addition of laemmli 
buffer and heat denaturing. For the A2 domain cleavage by thrombin, a master mix for 10 
reactions (1 U FVIII, 0.5 nM FIIa and 1x FIIa buffer per reaction) was prepared at 37°C. 
Aliquots were taken after the addition of FIIa every 15 seconds and reactions were stopped 
directly by mixing with laemmli buffer. Samples were then heat denatured at 95°C for 5 min. 
Heat denatured proteins were then separated by electrophoresis over SDS-polyacrylamide 
gels (7.5%). The proteins were transferred onto a PVDF membrane using a tank blotting 
apparatus (BioRad). The FVIII proteins were visualized by incubating the membrane with 
monoclonal anti-human FVIII A2 domain antibody (Green Mountain Antibodies; USA) using 
a 1:800 dilution, followed by incubation with a peroxidase conjugated anti-mouse IgG 
(1:4000 dilution). The final detection was achieved by adding 4 ml solution A, 400 µl solution 
B and 1.2 µl H2O2. Evaluation of bands was carried out using a chemillumiscence 
documentation system (Alpha Innotech). 
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3. Results: 
 
3.1 Functional studies on factor VIII protein variants containing different lengths of the 
B-domain: 
 
3.1.1 Construction (cloning) of expression plasmids containing different lengths of the B- 
domain 
 
The expression plasmids containing different lengths of the factor VIII B-domain region were 
constructed according to the cloning strategy that is detailed in section II.2.8 and documented 
in figure 15. The pMT2-F8-SNA intermediate vector (8808 bp; containing the SpeI / NruI / 
ApaI sites) was constructed by digesting pMT2-FVIII with ApaI and SpeI which will remove 
most of the middle part of FVIII cDNA (Fig. 7 step 1 and Fig. 15 B, lane 1). In the next step, 
a PCR fragment covering the end part of the B domain and part of the light chain (from 
position 6068 to position 7310 in pMT2-FVIII sequence) was created by two PCR rounds, the 
first PCR resulted in 1.25 kb fragment and introduced an NruI restriction site at the 5’-end, 
the second PCR resulted in a 1.27 kb fragment and introduced an SpeI restriction site 5’ to the 
NruI site (Fig. 7 step 2 and Fig. 15 A lane 1 / 2 and B lane 2). This fragment was then cloned 
into the large fragment that resulted from step 1. The large fragment contains the pMT2 
vector backbone and the beginning as well as the end of FVIII cDNA (Fig. 7 step 3). The 
selected pMT2-F8-SNA clones were confirmed to be correct by SalI digestion. This digestion 
resulted in a 5.8 kb fragment representing the vector backbone and a 3.0 kb factor VIII 
fragment (Fig. 15C). Clones were further confirmed by DNA sequencing. 
 
The different DNA fragments (AàE) containing various lengths of the B-domain region were 
amplified by PCR using the primer combinations listed in table 7 (Fig. 7 step 5 and Fig. 15 D 
and E). Those fragments were cloned into pMT2-F8-SNA which has been digested with SpeI 
and NruI (Fig. 7 step 4 and Fig. 15 F) to generate the plasmids pMT2-F8-BDD (10485 bp), 
pMT2-F8-101 (10788 bp), pMT2-F8-202 (11091), pMT2-F8-292 (11361 bp) and pMT2-F8- 
394 (11667 bp) (see appendix). Several clones were picked for each plasmid and tested to 
have the correct plasmid size by linearizing them with MluI (Fig.15 G) and by digesting them 
with SalI, which removes the FVIII cDNA from the vector (Fig.15 H). 
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Figure 7 (repeat): Schematic representation of the construction of various expression plasmids containing 
different lengths of the B domain. Steps 1,2 and 5 were performed using the pMT2-FVIII vector containing the 
full length FVIII cDNA (nts # 1111 to 8386). The B domain spans nts # 3388 to 6112 (aa 740 to 1648). 
 
A schematic representation of the various B domain deleted constructs on the protein level in 
comparison to the commercially available recombinant BDD-FVIII (ReFacto) and to the full 
length FVIII protein is shown in figure 16. The level of the B-domain glycosylation (the 
number of glycosylated positions) is also shown in the same figure. 
 
Figure 15 (next page): Overview of the various cloning steps used to construct the B-domain deleted 
expression plasmids. (A) The first PCR product that resulted in 1.25 kb fragment and the introduction of an 
NruI restriction site at the 5’-end. (B) Lane 2 shows the second PCR product which resulted in a 1.27 kb 
fragment and the introduction of an SpeI restriction site 5’ to the NruI site; Lane 1 shows the pMT2-FVIII 
plasmid digested with SpeI and ApaI. (C) Lane 1-3 represents SalI digestion (which releases the FVIII-cDNA 
from the pMT2 vector) of three pMT2-F8-SNA clones; Lane 4 represent SalI digestion of pMT2-FVIII 
containing the full length FVIII-cDNA. (D and E): The amplified different DNA fragments (AàE) containing 
various lengths of the B-domain. (F) SpeI/NruI (S/N) digestion of pMT2-F8-SNA (see Fig. 7; step 4). (G) MluI 
digestion of the different B-domain deleted plasmids. (H) SalI digestion of the different B-domain deleted 
plasmids. M: DNA molecular weight marker X (0.07 – 12.2 kb; Roche). 
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Figure 16: Schematic representation of the various B-domain deleted constructs on the protein level and the 
corresponding number of glycosylation sites within the B domain. 
 
One correct clone from each plasmid was amplified by maxi culture to be used in expression 
experiments. All maxi prepared clones were re-tested by MluI and SalI digestion (Fig. 17) 
and confirmed to be correct by DNA sequencing. Figure 18 shows the DNA sequence of 
different B-domain deleted constructs across the deleted region. Maxi-prepared DNA 
confirmed by restriction analysis and DNA sequencing was used for expression studies. 
 
 
Figure 17: Maxi prepared plasmid DNA of various B-domain deleted expression plasmids. Lane 1: MluI 
digested plasmids, Lane 2: SalI digested plasmids. L2: Gene Ruler 1kb DNA ladder (0.25 – 10 kb; Fermantas). 
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Figure 18: Representative DNA sequences of the different plasmids showing the DNA sequence across the 
deleted part of the B-domain region in each plasmid. A: pMT2-F8-BDD, B: pMT2-F8-101, C: pMT2-F8-202, D: 
pMT2-F8-292 and E: pMT2-F8-394. 
 
 56 
 
 
 
 
 
Figure 18: Representative DNA sequences of the different plasmids showing the DNA sequen e across the 
deleted par  of the B-domain region in each plasmid. A: pMT2-F8-BDD, B: pMT2-F8-101, C: pMT2-F8-202, D: 
pMT2-F8-292 and E: pMT2-F8-394. 
	   68	  
3.1.2 Transient expression of different B-domain deleted plasmids in three mammalian 
cell lines 
 
Transfection. The three cell lines were transfected by lipofection at 90% confluency. The 
transfection efficiency by Lipofectamine 2000 (Invitrogen) was checked by observing the 
intensity of the eGFP fluorescence 24 hours after transfection. The transfection with the eGFP 
containing plasmid (pEGFP-C1) was done in parallel along with the transfection of different 
B-domain deleted plasmids in the three cell lines (Fig. 19). 
 
FVIII activity. Two one-day (24 hours) medium collections were performed: 48 and 72 hours 
after transfection. The media were clarified by centrifugation and assayed for factor VIII 
activity using the clotting assay (section 2.4.2.1). 
 
Factor VIII activity (FVIII: C), given in percentage is shown for each cell line in figure 20 A, 
B and C. Within the two medium collections, the COS-7 cell line showed the highest 
expression level with an activity range of 20 to 56 % among all expressed plasmids, followed 
by HEK 293T with a range of 11.2 to 41.1 % FVIII: C and the CHO cell line with a range of 
1.7 to 7.5 % FVIII: C. Negative controls (no DNA in the transfection mixtures) showed no 
factor VIII activity. 
 
The first medium collection (48 hours after transfection) showed higher activity in HEK 293T 
and COS-7 cells for all the expressed plasmids while the second medium collection (72 hours 
after transfection) showed higher activity in CHO cells. 
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Figure 19: Lipofection efficiency as a transfection method in various cell lines used. A, C and E: Non- 
transfected negative control cultures of HEK 293T, COS-7 and CHO cell lines respectively. B, D and F: 24 
hours pEGFP-C1 transfected cultures of HEK 293T, COS-7 and CHO cell lines respectively. 
 
Activity levels for different constructs in different cell lines were compared in each medium 
collection (Fig. 20 D and E). In comparison to the BDD construct, the data showed that the 
FVIII activity levels are generally higher in the constructs containing added lengths of the B- 
domain in COS-7 and HEK 293T cells. Additionally, with the exception of the 292 construct, 
the different constructs showed an in increase in the FVIII: C with the increase in the B- 
domain length in both cell lines (COS-7 and HEK 293T). 
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Figure 20: Transient expression of the different constructs in HEK 293T, COS-7 and CHO-DHFR[-] cell 
lines. A, B and C: FVIII: C in two medium collections for different constructs in CHO, 293T and COS-7 cells 
respectively. D and E: Activity levels for different constructs in different cell lines were compared for each 
medium collection. All data are means ± SD. 
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3.1.3 Functional studies on different B-domain deleted plasmids transiently expressed in 
COS-7 cells 
 
The COS-7 cell line that showed the highest factor VIII expression (section 3.1.2) was used 
for further functional assessment of the different B-domain deleted plasmids. For this, COS-7 
cells were transfected with the different constructs at 90% confluence. Conditioned medium 
and cellular lysates collected 48 hours after transfection were used for activity and antigen 
assessment. All activity and antigen values mentioned in this section are per one million cells 
per milliliter. 
 
FVIII activity and antigen. Collected media were clarified by centrifugation and assayed for 
factor VIII activity using the clotting and the chromogenic assays (section 2.4.2). For factor 
VIII antigen determination, an ELISA assay was used (section 2.4.3). After medium 
collection, cells were washed directly with PBS, trypsinized, counted and then lysed. Lysates 
were only used for antigen quantification. 
 
FVIII Activity levels of the two different assay methods are shown in figure 21 A. The 
clotting assay showed a slightly higher value than the chromogenic assay for all the 
constructs. However, for the BDD construct, the FVIII: C of chromogenic assay was higher 
than FVIII: C of clotting assay. As already seen before (3.1.2), the data show that the activity 
levels are higher in the constructs containing added lengths of the B-domain in comparison to 
the BDD construct. With the exception of the 292 construct, the different constructs showed 
an in increase in the FVIII: C with the increase in the B-domain length in both assays 
methods. 
 
Antigen levels in both the conditioned medium and cellular lysates are shown in figure 21 B. 
For all expressed plasmids, the FVIII: Ag levels in the medium are much lower than in the 
lysates. With the exception of the 292 construct, the FVIII: Ag levels are higher in the 
expression of the constructs containing added lengths of the B-domain in comparison to the 
BDD construct in medium and lysates. The different constructs showed an increase in the 
FVIII: Ag with the increase in the B-domain length in the medium except for the 292 
construct. 
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Figure 21: Activity and antigen levels of the different constructs expressed in COS-7 cell line for 48 hours. 
(A) FVIII: C levels in conditioned medium using the clotting and the chromogenic assays. (B) FVIII: Ag levels 
in medium and in cellular lysates. All data are means ± SD; *: p value < 0.05. 
 
Specific activity. The functionality of the different constructs was evaluated by their specific 
activity. The specific activity was calculated by dividing the activity of each construct 
(measured by the clotting assay) by its corresponding FVIII: Ag value (measured by ELISA) 
in medium. Considering that normal plasma has an activity of one unit per milliliter and 
assuming that the one unit FVIII contains 0.15 µg FVIII protein per milliliter (FVIII 
concentration varies in different publications with a range of 100-300 ng / ml), then the 
optimal specific activity of FVIII is 6.67 U/µg. 
 
Figure 22 A shows the calculated specific activities of FVIII expressed from different 
constructs. The data shows that all the constructs are functional with specific activities above 
the calculated optimal specific activity. The different constructs containing added lengths of 
the B-domain show higher specific activity in comparison to the BDD construct. 
Interestingly, the 292 construct that has the lowest FVIII: C and FVIII: Ag compared to the 
other constructs showed the highest specific activity. 
 
Total expressed FVIII. The total expressed FVIII protein of the different constructs is 
measured as the sum of the quantity of protein secreted into the medium and that retained in 
cellular lysates (Fig. 22 B). Data indicate that the different constructs containing added 
lengths of the B-domain show the higher total protein quantity. With the exception of the 292 
construct, the total expressed FVIII increased with the increase in the B-domain length. 
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Figure 22: Specific activity of the different expressed FVIII proteins and the total expressed FVIII in 
COS-7 cells. (A) The specific activity of different constructs as unit per µg FVIII in conditioned medium. (B) 
The total expressed FVIII (in medium and cellular lysate) of the different constructs. 
 
3.1.4 Generation of stable cell lines in CHO-DHFR[-] cells 
 
Linearized, ethanol precipitated expression plasmids representing the different B-domain 
deleted constructs were transfected by lipofection into CHO-DHFR[-] cells (see section 
2.3.3.1). Two days later, the cells were splitted. 
 
Selection. Transfected cells were selected for plasmid uptake by culturing them in nucleoside 
deficient complete medium and in different concentrations of MTX. The medium was 
changed every second day until well-defined new colonies appeared 2-3 weeks after selection 
(see Fig. 23). New colonies were then pooled and assayed for FVIII: C upon confluency. As a 
result, only the CHO-BDD, CHO-202, CHO-394 and CHO-full-length cultures showed FVIII 
productivity at a certain MTX concentration upon selection (see table 9, selection part). 
Productive cultures were expanded into many dishes for storage, amplification and cloning. 
 
Limited dilution cloning. Productive cultures from the four stable cultures were cloned by 
limited dilution cloning (see section 2.3.3.2). For this, minimums of three serially diluted 96- 
well plates were made for each stable culture. Approximately, 20 to 40 wells per construct 
were marked as having a single cell. Single cells were followed for two weeks until they 
reached full colonies. A maximum of 24 colonies arose from single cells were propagated into 
24-well plates, each in a well until a confluent culture is reached. Conditioned medium was 
then collected and assayed for FVIII productivity. 
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(see Fig. 23). New colonies were then pooled and assayed for FVIII: C upon confluency. As a 
result, only the CHO-BDD, CHO-202, CHO-394 and CHO-full-length cultures showed FVIII 
productivity at a certain MTX concentration upon selection (see table 9, selection part). 
Productive cultures were expanded into many dishes for storage, amplification and cloning. 
 
Limited dilution cloning. Productive cultures from the four stable cultures were cloned by 
limited dilution cloning (see section 2.3.3.2). For this, minimums of three serially diluted 96-
well plates were made for each stable culture. Approximately, 20 to 40 wells per construct 
were marked as having a single cell. Single cells were followed for two weeks until they 
reached full colonies. A maximum of 24 colonies arose from single cells were propagated into 
24-well plates, each in a well until a confluent culture is reached. Conditioned medium was 
then collected and assayed for FVIII productivity. 
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Figure 23: Examples of well-defined new colonies appeared 2-3 weeks after selection procedure. (A) A new 
colony appeared upon selection of pMT2-F8-BDD transfected cells. (B) A new colony appeared upon selection 
of pMT2-F8-394 transfected cells. 
 
With this approach, a few productive clones were identified with increased FVIII: C for each 
stable culture. The highest identified productive clones (CHO-BDD clone F2, CHO-202 clone 
G3, CHO-394 clone F4 and CHO-Full clone C6) are listed in table 9 (cloning part) with their 
respective MTX concentration and FVIII: C. Productive clones were expanded for storage, 
amplification and sub-cloning. 
 
Amplification. Clones that still show low FVIII: C after the cloning procedure (CHO-202 
clone G3 and CHO-394 clone F4) was amplified (section 2.3.3.1). One amplification step 
(MTX concentration from 200 nM to 800 nM) for CHO-394 clone F4 was enough to increase 
the productivity more than four times (16% to 77%) and several amplification steps (MTX 
concentration from 400 nM to 6.0 µM) were required for CHO-202 clone G3 to increase the 
productivity more than 5 times (5% to 28%) (Table 9, Amplification). The new more 
productive cultures were also expanded, stored and further sub-cloned. 
 
Sub-cloning. Sub-cloning was performed for moderately productive cell lines (CHO-BDD 
clone F2, CHO-202 clone G3 and CHO-394 clone F4) using the same limited dilution 
approach (see limited dilution cloning section) to guarantee the clonality of the new cell lines 
and to obtain a higher productive cell lines. The MTX concentration corresponds to the latest 
concentration used (in amplification or in cloning steps). Sub-cloning resulted in the 
following high productive cell lines: CHO-BDD clone F2H1, CHO-202 clone G3E6 and 
CHO-394 clone F4F3 (Table 9, Sub-cloning). 
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Table 9: FVIII productivity at different stages of stable cell lines generation.  
* FVIII activity is per 1*106 cells per 24 hours. 
 
3.1.5 Purification and thrombin activation of different recombinant FVIII proteins 
 
The four high productive stable cell lines, CHO-BDD (clone F2H1), CHO-202 (clone G3E6), 
CHO-394 (clone F4F3) and CHO-Full (clone C6), were expanded in complete medium 
containing the corresponding MTX concentration. For each cell line, 300 ml medium was 
collected and ten folds concentrated. FVIII: C were measured after concentration using the 
clotting assay (section 2.4.2.1) and was > 300 % for all of them. 
 
FVIII purification. FVIII protein in the concentrated medium (30-35 ml) was captured by 
FVIII-Select beads (section 2.4.1). Beads were then washed and FVIII was then eluted as 
batches by buffer B. The FVIII: C of the 8 collected batches for each cell line was tested and 
found to be above 300 % in all the collected batches from the four different cell lines. 
 
Productive batches were then pooled, buffer exchanged and concentrated (section 2.4.1). 
Concentrated material (∼ 250 µl) containing purified FVIII protein were tested for FVIII: C 
and FVIII: Ag (see tables 10 and 11). 
 
 
Table 10: FVIII activity (Clotting assay) of the purified products diluted 1:100 in FVIII deficient plasma. 
 
 
Table 11: FVIII antigen concentration of the purified products diluted 1:100 in buffer A. 
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 Selection Cloning Amplification Sub-cloning 
 MTX Activity* Clone MTX Activity* Clone MTX Activity* Clone MTX Activity* 
CHO-BDD 200 nM 6 % F2 200 nM 55 % - - - F2H1 
200 
nM 90 % 
CHO-202 400 nM 2 % G3 400 nM 5 % G3 
6.0 
uM 28 % G3E6 
6.0 
!M 50 % 
CHO-394 200 nM 9 % F4 200 nM 16 % F4 
800 
nM 77 % F4F3 
800 
nM >150 % 
CHO-Full 600 nM 264% C6 600 nM >250 % - - - - - - 
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FVIII activation by thrombin. Purified FVIII proteins were activated by thrombin (Factor 
IIa) and the A2 domain cleavage (see fig. 4) was assessed according to section 2.4.4. For this, 
a master mixture for ten reactions (1 U FVIII, 0.5 nM FIIa and 1x FIIa buffer per reaction) 
was prepared at 37 °C. Aliqoutes were collected every 15 seconds and reactions were stopped 
by mixing them with sample loading buffer directly. Samples were then heat denatured and 
run over PAGE, western blotted against PVDF membrane and detected by an antibody 
against the A2 domain. Figure 24 show the western blots of the A2 generation for the purified 
FVIII- BDD and FVIII-394 proteins. The rate of A2 generation was calculated as a 
percentage by dividing the generated A2 domain band density (integrated density value) by 
the total A2 density in the reaction (A2 domain band, A1+A2 domains band and any 
undigested FVIII material). Data in figure 25 show that the BDD construct is slightly faster 
activated as compared to the 394 construct, since it showed higher A2 generation at point zero 
and reached a 50% A2 generation in a shorter time. 
 
 
Figure 24: Western blots demonstrating A2 generation of purified FVIII-BDD and FVIII-394 proteins at 
different time points after thrombin digestion. 
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Figure 25: Rate of A2 domain generation measured in 15-second intervals. The BDD construct shows a 
higher A2 generation at point zero and over time a faster A2 generation than the 394 construct. 
 
3.2 Construction of a new helper vector for the production of helper-dependent 
adenovectors for the use in hemophilia gene therapy 
 
3.2.1 Construction of the plasmid pBac-AAV2-Ad5 
 
The shuttle plasmid pBac-AAV2-Ad5LR (∼8777 bp) was generated by introducing an 
AAV2- 5’ITR / Ad5LR / AAV2-3’ITR construct into the basic plasmid pFastBac-1 (see 
section 2.2.10). The shuttle plasmid was then linearized with PmeI (Fig. 26 A), purified, 
dephosphorylated and then mixed with pAdEasy-1 containing the adenoviral genome from 
3.5 to 36 kb (Fig. 26 B) in BJ8153 electrocompetent cells. The cells were then electroporated. 
Electroporation resulted in the introduction of the Ad5-genome into the shuttle plasmid by 
homologous recombination and the generation of pBac-AAV2-Ad5 (∼35824 bp). Figure 26 
C shows a mini prepared DNA of several picked pBac-AAV2-Ad5 clones from the 
electroporation plates. Possibly correct clones are those that show a super coiled and a relaxed 
band above the marker level (above the 12.2 kb band), which reflect a size of ∼35 kb. Those 
clones were further characterized by restriction enzyme analysis. Clones that showed smaller 
size fragments (lower than 12.2 kb band) were neglected (those clones are marked by an x in 
fig. 26 C). Possibly correct clones were stabilized by transforming them into XL10-Gold 
bacteria; DNA was then mini prepared (Fig. 27 A). 
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Figure 26: Cloning of pBac-AAV2-Ad5. (A) Linearization of the shuttle plasmid pBac-AAV2-Ad5LR (∼8.7 
kb). (B) pAdEasy-1 (∼34 kb). (C) Mini prepared clones picked from the electroporation plates. Lanes labeled 
with x stands for wrong clones (don’t have the expected size). L3: 1kb DNA ladder (0.5 – 10 kb; New England 
Biolabs); M: DNA molecular weight marker X (0.07 – 12.2 kb; Roche). 
 
Clones with correct size (clones 1,2,4,5and 6 in Fig. 27 A) were further characterized by 
restriction analysis and DNA sequencing of the adenoviral construct borders. Digestion with 
SmaI (which should give the following fragments: 6447, 11, 195 [5'-ITR], 2463, 6480, 1398, 
4456, 1455, 3540, 3386, 230, 652, 2278, 2262, 550 [3'-ITR] and 11 bp) confirmed the 
presence of the Ad5 genome insert, however showed a deletion in the 3’ITR region. 
Normally, SmaI should cut twice in each ITR region, however the loss of its cut sites in the 
3’ITR (positions 34153 and 34164 in the pBac-AAV2-Ad5 genome) resulted in joining the 
fragments 6447,550 and 11 bp in one band: 7008 bp (Fig. 27 B). 
 
 
Figure 27: Characterization of pBac-AAV2-Ad5. (A) DNA mini preparation of selected clones after transforming 
the possible correct pBac-AAV2-Ad5 clones into XL10-Gold bacteria. (B) SmaI map of pBac- AAV2-Ad5 clones that 
shows the absence of 6447, 550 and 11 bp fragments and the presence of a 7 kb band instead. M: DNA molecular 
weight marker X (0.07 – 12.2 kb; Roche). L2: Gene Ruler 1kb DNA ladder (0.25 – 10 kb; Fermentas). 
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DNA sequencing across the 5’ITR region (using the primer Ad5-4231a, see section 2.2.10) 
revealed an intact 5’ITR. DNA sequencing across the 3’ITR region using the primer Ad5- 
35687s confirmed a 3’ITR deletion from nt 34120 until 34249 (Fig. 28). 
 
pBac-EGFP and pBac-AAV2-Rep were constructed according to the cloning strategy outlined 
in section 2.2.10. Expression of the AAV2-Rep gene was tested in both Sf9 and 293T cells. 
SF9 cells were transfected with pBac-AAV2-Rep for 48 hours and total RNA was then 
extracted (see section 2.2.2 and 2.2.10). Total RNA was subject for RT PCR using 
Superscript III reverse transcriptase. Taq-PCR was performed using the primer pairs AAV2- 
2310a / AAV2-1380s and AAV2-2310a / AAV2-321s. Both gave the expected PCR product 
of 1.0 kb and 2.0 kb, respectively (Fig. 29 lanes 2 &3 and 5 & 6). 293T cells were transfected 
with pBac-AAV2-Rep and pDG (as a positive control for Rep gene expression) plasmids for 
48 hours and total RNA was then extracted (see section 2.2.2 and 2.2.10). Again, total RNA 
was subjected for RT PCR using the primer pairs AAV2-2310a / AAV2-1380s and AAV2- 
2310a / AAV2-321s. Both gave the expected product of 1.0 kb and 2.0 kb, respectively (Fig. 
29 lanes 8 & 9 for pDG and 10 & 11 for pBac-AAV2-Rep using the first primer pair and 
lanes 13 & 14 for pDG and 15 & 16 for pBac-AAV2-Rep using the second primer pair). 
 
 
Figure 28: DNA sequence of pBac-AAV2-Ad5 3’ITR region. The white arrow indicates the deletion place 
where the pBac-AAV2-Ad5 sequence stopped at position 34121 and continued at position 34250. 
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Figure 29: Testing the expression of the AAV2-Rep gene in SF9 and 293T cells. RT-PCR for Rep expression 
in SF9 cells (lanes 1 to 6) and in 293T cells (lanes 7 to 16). Lanes 1,4,7 and 12 are negative controls. M: DNA 
molecular weight marker X (0.07 – 12.2 kb; Roche). 
 
3.2.2 Generation of the bacmid bBac-AAV2-Ad5 
 
Recombinant bacmids were generated by site-specific transposition in DH10Bac cells that 
contain the baculovirus shuttle vector (bacmid). The plasmids pBac-AAV2-Ad5, pBac-EGFP 
and pBac-MMTV-bGH-AAVRep served as shuttle vectors to generate the recombinant 
bacmids bBac-AAV2-Ad5, bBac-EGFP and bBac-AAV2-Rep respectively in DH10Bac cells 
according to the protocol detailed in section 2.2.10. 
 
Recombinant bacmid DNA was isolated according to Bac-to-Bac Baculovirus Expression 
System manual (section 2.2.1). Figure 30 A shows six selected bBac-AAV2-Ad5 clones. 
Those clones were characterized by Taq-PCR analysis. When we amplified them with M13 
forward and reverse primers (which cover all the insert region), no product could be seen 
(Fig. 30 B) which reflects the presence of our expected very large insert within the bacmid 
DNA. After amplifying them with M13 forward / Ad5-4231a primers we could see a ∼3.1 kb 
product (Fig. 30 D left) which confirms the presence of the 5’ITR end. The amplification of 
the 3’ITR-end (primers Ad5-35687s / M13 reverse) resulted in a ∼1.55 kb product (Fig. 30 D 
right) which confirms the presence of the 3’ITR end. Figure 32 C shows an example of empty 
bacmids where amplification by M13 forward and reverse primers resulted in a 273 bp 
product. bBac-EGFP was used as a positive control for M13 forward and reverse 
amplifications (marked P; Fig. 30 B and C) and resulted in a product of ∼ 3.6 kb. 
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Figure 29: Testing the expression of the AAV2-Rep g ne in SF9 and 293T cells. RT-PCR for R p expression 
in SF9 cells (lanes 1 to 6) and in 293T cells (lanes 7 to 16). Lanes 1,4,7 and 12 ar  negative controls. M: DNA 
molecular weight marker X (0.07 – 12.2 kb; Roche). 
 
3.2.2 Generation of the bacmid bBac-AAV2-Ad5 
 
Recombinant bacmids were generated by site-specific transposition in DH10Bac cells that 
contain the baculovirus shuttle vector (bacmid). The plasmids pBac-AAV2-Ad5, pBac-EGFP 
and pBac-MMTV-bGH-AAVRep served as shuttle vectors to generate the recombinant 
bacmids bBac-AAV2-Ad5, bBac-EGFP and bBac-AAV2-Rep respectively in DH10Bac cells 
according to the protocol detailed in section 2.2.10. 
 
Recombinant bacmid DNA was isolated according to Bac-to-Bac Baculovirus Expression 
System manual (section 2.2.1).  Figure 30 A shows six selected bBac-AAV2-Ad5 clones. 
Those clones were characterized by Taq-PCR analysis. When we amplified them with M13 
forward and reverse primers (which cover all the insert region), no product could be seen 
(Fig. 30 B) which reflects the presence of our expected very large insert within the bacmid 
DNA. After amplifying them with M13 forward / Ad5-4231a primers we could see a !3.1 kb 
product (Fig. 30 D left) which confirms the pr sence of the 5’ITR end. The amplification of 
the 3’ITR-end (primers Ad5-35687s / M13 reverse) resulted in a !1.55 kb product (Fig. 30 D 
right) which confirms the presence of the 3’ITR end. Figure 32 C shows an example of empty 
bacmids where amplification by M13 forward and reverse primers resulted in a 273 bp 
product. bBac-EGFP was used as a positive control for M13 forward and reverse 
amplifications (marked P; Fig. 30 B and C) and resulted in a product of ! 3.6 kb. 
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Figure 30: Characterization of bBac-AAV2-Ad5 by Taq-PCR. (A) Isolated bacmid DNA from a selected 
bBac-AAV2-Ad5 clones. Those clones were characterized by Taq-PCR using M13 forward and reverse primers 
(Image B), M13 forward / Ad5-4231a primers (Image D left) and Ad5-35687s / M13 reverse primers (Image D 
right). (C) Is an example of empty bacmids. P: bBac-EGFP as a positive control for M13 forward and reverse 
amplifications. L3: 1kb DNA ladder (0.5 – 10 kb; New England Biolabs); M: DNA molecular weight marker X 
(0.07 – 12.2 kb; Roche). 
 
bBac-AAV2-Rep was also characterized by Taq-PCR. Amplifying 10 selected clones by M13 
forward and reverse primers resulted in a 5.3 kb PCR product in clones 1,2,3,5,6,7,8 and 9 
and a 273 bp PCR product in clones 4 and 10 (Fig. 31 A). While the 5.3 kb product confirms 
the existence of an MMTV(promoter)-AAVRep insert in the bacmid DNA, the 273 bp 
product indicates empty clones. To further confirm the presence and the integrity of the 
MMTV(promoter)-AAVRep insert, the 5’-end of the insert were amplified with M13 forward 
/ MMTV-1347a primers and the 3’-end were amplified with AAV2-321s / M13 reverse 
primers. Both resulted in the expected 2.3 kb and 2.8 kb PCR products in the same positive 
clones respectively (Fig. 31 B & C). 
 
 70 
 
Figure 30: Characterizati n of bBac-AAV2-Ad5 by Taq-PCR. (A) Isolated bacmid DNA from a sel cted 
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(0.07 – 12.2 kb; Roche). 
 
 
bBac-AAV2-Rep was also characterized by Taq-PCR. Amplifying 10 selected clones by M13 
forward and reverse primers resulted in a 5.3 kb PCR product in clones 1,2,3,5,6,7,8 and 9 
and a 273 bp PCR product in clones 4 and 10 (Fig. 31 A). While the 5.3 kb product confirms 
the existence of an MMTV(promoter)-AAVRep insert in the bacmid DNA, the 273 bp 
product indicates empty clones. To further confirm the presence and the integrity of the 
MMTV(promoter)-AAVRep insert, the 5’-end of the insert were amplified with M13 forward 
/ MMTV-1347a primers and the 3’-end were amplified with AAV2-321s / M13 reverse 
primers. Both resulted in the expected 2.3 kb and 2.8 kb PCR products in the same positive 
clones respectively (Fig. 31 B & C).  
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Figure 31: Characterization of bBac-AAV2-Rep by Taq-PCR. Ten isolated bBac-AAV2-Rep clones were 
characterized by Taq-PCR using M13 forward and reverse primers (Image A), M13 forward / MMTV-1347a 
primers (Image B) and AAV2-321s / M13 reverse primers (Image C). L1: Gene Ruler DNA ladder mix (0.1 – 10 
kb; Fermantas). 
 
3.2.3 Generation of helper recombinant baculovirus in insect cells 
 
3.2.3.1 Transfection of SF9 cells with bacmid DNA and collection of P1 viral stock 
 
SF9 cells (Fig. 32 A) were seeded at 9 * 105 cells per well in 6 well plates. After attachment, 
they were transfected with 1.0 µg purified bacmid DNA (bBac-AAV2-Ad5 and/or bBac- 
AAV2-Rep) according to section II.3.4.1. Two days after transfection, SF9 cells showed an 
increase in cellular diameter. Three days after transfection, SF9 cells showed a cessation of 
growth, cellular swelling and granular appearance which indicates viral budding (Fig. 32 B, 
C). One day later, cells show massive detachment and lysis. 
 
Medium were collected on the fourth day after transfection in sterile tubes, centrifuged and 
the clarified supernatant containing the virus was then transferred into a fresh tube and labeled 
as P1 viral stock for vBac-AAV2-Ad5 as well as for vBac-AAV2-Rep. 
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characterized by Taq-PCR using M13 forward and r v rse primers (Image A), M13 forward / MTV-1347a 
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3.2.3 Generation of helper recombinant baculovirus in insect cells 
 
3.2.3.1 Transfection of SF9 cells with bacmid DNA and collection of P1 viral stock 
 
SF9 cells (Fig. 32 A) were seeded at 9 * 105 cells per well in 6 well plates. After attachment, 
they were transfected with 1.0 !g purified bacmid DNA (bBac- AV2-Ad5 and/or bBac-
AAV2-Rep) according to section II.3.4.1. Two days after transfection, SF9 cells showed an 
increase in cellular diameter. Three days after transfection, SF9 cells showed a cessation of 
growth, cellular swelling and granular appe rance which indicates viral budding (Fig. 32 B, 
C). One day later, cells show massive detachment and lysis. 
 
Medium were collected on the fourth day afte  transfection in sterile tubes, centrifuged and 
the clarified supernatant containing the virus was then transferred into a fresh tube and lab led 
as P1 viral stock for vBac-AAV2-Ad5 as well as for vBac- AV2-Rep. 
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Figure 32: Transfection of SF9 cells: (A) confluent wild type SF9 culture (10x magnification). (B) SF9 cells 
three days after transfection with bBac-AAV2-Ad5 (10x magnification). The cells show cellular swelling and 
granular appearance. (C) A 20x magnification of a part of foto (B) where arrows indicate cells with granulation 
due to viral budding. 
 
3.2.3.2 Amplification of P1 viral stock 
 
To obtain a higher titer ranging from 1 * 107 to 1 * 108 pfu/ml, P1 viral stock was amplified in 
SF9 cells. 0.04 ml P1 viral inoculum were used to infect SF9 cells seeded at 2 * 106 cells per 
well in 6-well plates. Two days after infection, SF9 cells showed all the signs of infection 
(Increased cell diameter, cessation of growth, granular appearance, detachment and cell lysis). 
Medium containing the virus was collected, pelleted and the clarified supernatant was 
transferred into a fresh tube labeled P2 viral stock. 
 
3.2.3.3 Viral purification: Plaque assay 
 
Clarified baculoviral stock P2 (from vBac-AAV2-Ad5 and vBac-AAV2-Rep) was diluted to 
an 8-log serial dilution and 1.0 ml inoculum was used to infect wild type SF9 cells seeded at 1 
* 106 cells per well in 6-well plates for one hour (see section 2.3.4.3). The medium was then 
replaced by a plaquing medium and plates were incubated until plaques formation. 
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Ten days later, plaques were visible at all viral dilutions wells (Fig. 33) and countable only at 
the highest dilution (10-8). Infection with vBac-AAV2-Ad5 P2 viral stock resulted in the 
appearance of 50 plaques at 10-8 dilution, which reflects a viral titer of 5 * 109 pfu/ml. 
Infection with vBac-AAV2-Rep P2 viral stock resulted in the appearance of 40 plaques at 10-8 
dilution, which reflects a viral titer of 4 * 109 pfu/ml. The titer of the viral stock was then 
calculated according to the following formula: 
 
                                                                                                     1  
Titer (pfu/ml) = number of plaques * dilution factor * ...........................  
                                                                                      ml of inoculum / well 
 
 
Figure 33: Palques of vBac-AAV2-Ad5 in SF9 cells. (A) 10 days after infection with vBac-AAV2-Ad5 (10x 
magnification). (B) Is a 20x magnification of the plaque in photo A. 
 
A viral stock from single viral clones was generated by plaque purification. Clear well 
separated plaques were picked (20 plaques for vBac-AAV2-Ad5 and 10 for vBac-AAV2- 
Rep) and each agarose plug was transferred separately into 500 µl Grace’s medium, mixed 
and used to infect one well of SF9 cells seeded at 1 * 106 cells per well in 6-well plates. Three 
days later, the plaque purified viral stock was collected and then amplified according to 
section 2.3.4.2. 
 
3.2.3.4 PCR analysis of the purified virus 
 
Purified viral DNA was extracted from the purified amplified viral stock using the extra 
chromosomal DNA isolation protocol (see section 2.2.1). Two viral DNA clones (originating 
from two different plaques) from vBac-AAV2-Ad5 as well as from vBac-AAV2-Rep were 
verified by Taq-PCR. 
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Figure 33: Palques of vBac-AAV2-Ad5 in SF9 cells. (A) 10 days after infection with vBac-AAV2-Ad5 (10x 
magnification). (B) Is a 20x magnification of the plaque in photo A. 
 
A viral stock from single viral clones was generated by plaque purification. Clear well 
separated plaques were picked (20 plaques for vBac-AAV2-Ad5 and 10 for vBac-AAV2-
Rep) and each agarose plug was transferred separately into 500 !l Grace’s medium, mixed 
and used to infect one well of SF9 cells seeded at 1 * 106 cells per well in 6-well plates. Three 
days later, the plaque purified viral stock was collected and then amplified according to 
section 2.3.4.2. 
 
3.2.3.4 PCR analysis of the purified virus 
 
Purified viral DNA was extracted from the purified amplified viral stock using the extra 
chromosomal DNA isolation protocol (see section 2.2.1). Two viral DNA clones (originating 
from two different plaques) from vBac-AAV2-Ad5 as well as from vBac-AAV2-Rep were 
verified by Taq-PCR.  
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Amplification of vBac-AAV2-Ad5 clones (plaques 9 and 16 in Fig. 34 A) with M13 forward 
and reverse primers that cover the whole insert region resulted in no product (Fig. 34 A, a), 
which reflects the presence of our very large insert (Ad5 genome) within the baculoviral 
genome. Amplifying them with M13 forward / Ad5-4231a primers resulted in a ∼3.1 kb 
product (Fig. 34 A, b) which confirms the presence of the 5’ITR region (the 5’ end of the 
insert). Amplifying them with Ad5-35687s / M13 reverse primers resulted in a ∼1.55 kb 
product (Fig. 34 A, c) which confirms the presence of the 3’ITR region (the 3’ end of the 
insert). The two clones were also amplified with Ad5-4000xs / Ad5-7000a primers (cover part 
of the Ad5 sequence) which gave a 3.0 kb band (Fig. 34 A, d) and further confirmed the 
presence of the Ad5 insert. 
 
vBac-AAV2-Rep clones (plaques 1 and 5 in Fig. 34 B) were also characterized by Taq-PCR. 
Amplification with M13 forward and reverse primers that cover the whole insert region and 
resulted in a 5.3 kb PCR product (Fig. 34 B, a) which confirms the existence of our MMTV- 
AAVRep insert in the viral DNA. PCR amplification with M13 forward / MMTV-1347a 
primers resulted in a 2.3 kb PCR product which double confirms the 5’-end of the insert (Fig. 
34 B, b). Amplification with AAV2-321s / M13 reverse primers that cover the 3’ end of the 
insert further confirmed the existence of an intact MMTV-AAVRep insert and resulted in a 
2.8 kb PCR product (Fig. 34 B, c). 
 
 
Figure 34: Characterization of vBac-AAV2-Ad5 and vBac-AAV2-Rep by Taq-PCR. (A) Two clones of 
vBac-AAV2-Ad5 were amplified by Taq-PCR using M13 forward and reverse primers which cover the whole 
insert region (a), M13 forward / Ad5-4231a primers which cover the 5’ end of the insert (b), Ad5-35687s / M13 
reverse primers which cover the 3’ end of the insert (c) and Ad5-4000xs / Ad5-7000a primers which cover part 
of the Ad5 sequence (d). (B) Two vBac-AAV2-Rep clones were characterized by Taq-PCR using M13 forward 
and reverse primers which cover the whole MMTV-AAVRep insert (a), M13 forward / MMTV-1347a primers 
which cover the 5’ end of the insert (b) and AAV2-321s / M13 reverse primers which cover the 3’ end of the 
insert (c). L1: Gene Ruler DNA ladder mix (0.1 – 10 kb; Fermantas). 
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3.2.4 Rescuing the helper dependent adenovirus in HEK 293T cells 
 
The ability of the baculovirus to infect HEK 293 was tested. Confluent HEK 293 cells were 
infected with 200 µl vBac-EGFP P2 viral stock once for one hour at 37 °C and once for four 
hours at 28 °C (see infection protocol, section 2.3.5). One day after infection, cultures were 
observed under UV light and found to be efficiently infected in both conditions as can be seen 
by GFP fluorescence (Fig. 35). 
 
HEK 293 cells were transfected at 90% confluence with a linearized mini-Ad5 helper 
dependent vector (pAd5-AAT-hf8), which contains the human factor VIII cDNA, by 
lipofection in 6-well plates. Cells were then infected with vBac-AV2-Ad5 clones at 2000 and 
500 MOI in combination with vBac-AAV2-Rep particles at 200 MOI as detailed in table 8. 
One well was infected only with vBac-AAV2-Rep as a negative control for infection. 
Infection mixtures were incubated with cells for 5 hours and medium was changed then. 
 
 
Figure 35: The ability of the baculovirus to infect HEK 293 cells. A: HEK 293 cells infected with vBac- 
EGFP for one hour at 37 °C. B: HEK 293 cells infected with vBac-EGFP for four hours at 28 °C. 
 
Four days after infection (five days after transfection), medium was collected and cells were 
washed with PBS and lysed by four rouds of freeze / thaw cycles. Medium was concentrated 
10 times, assayed for FVIII: Ag and showed no FVIII antigen in all wells. Extra chromosomal 
DNA was isolated from cellular lysates according to section 2.2.1. Gel elctrophoresis of 2 µl 
of the extracted extra chromosomal DNA showed a fragment representing the size of a 
linearized mini-Ad5 helper dependent vector in all the wells (Fig. 36, lanes marked a). 
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Four days after infection (five days after transfection), medium was collected and cells were 
washed with PBS and lysed by four rouds of freeze / thaw cycles. Medium was concentrated 
10 times, assayed for FVIII: Ag and showed no FVIII antigen in all wells. Extra chromosomal 
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To decide whether the extracted extra chromosomal DNA resulted from the original 
introduced plasmid or has been produced inside HEK 293 cells under the support of our 
helper hybrid virus, the extra chromosomal DNA was digested with DpnI. Gel electrophoresis 
of 10 µl DpnI digested DNA showed the disappearance of the extra chromosomal DNA 
fragment (Fig. 36, lanes marked b). Cellular lysates were used for a second round of infection 
(according to section 2.3.5). No signs of viral production were seen over four days. Cells were 
then lysed and lysates were used for extra chromosomal DNA isolation. DpnI digestion 
showed the same result. Lysates (from the second round of infection) were used for a third 
round of infection that showed the same result. 
 
The disappearance (digestion) of the extra chromosomal DNA after DpnI digestion indicates 
that it was all from bacterial origin and our designed helper hybrid virus (vBac-AAV2-Ad5 in 
combination with vBac-AAV2-Rep) could not support an in vivo production of the helper 
dependent vector. 
 
 
Figure 36: DpnI digestion of extra chromosomal DNA. Extra chromosomal DNA was isolated from cellular 
lysates (lanes marked a) representing different infection wells (wells 3à8 according to table 8). DpnI digestion 
showed no product indicating totally degraded material (lanes b). L2: Gene Ruler 1kb DNA ladder (0.25 – 10 
kb; Fermantas). 
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4. Discussion: 
 
4.1 Functional studies on factor VIII protein variants containing different lengths of the 
B-domain 
 
Haemophilia A is an X-linked hereditary deficiency of functional coagulation factor VIII 
(FVIII). In the absence of treatment, patients with severe haemophilia A (plasma levels of 
FVIII below 1% of normal) will suffer repeated bleeds, often in muscles and joints. To 
prevent this development, patients with severe haemophilia A are treated with recombinant or 
plasma-derived FVIII concentrates (Christiansen et al., 2010). Recombinant FVIII has 
become the preferred form of factor replacement for hemophilia A patients as it eliminates the 
risk of transmission of human blood-borne infections (Rogoff et al., 2002; Key and Negrier, 
2007). Current developments in rFVIII technology have enabled the production of rFVIII 
devoid of any human protein exposure during the cell culture fermenting process and in final 
formulation (Mitterer et al., 2003). 
 
Two forms of recombinant FVIII are currently manufactured: full-length recombinant FVIII 
(FL-rFVIII) and B-domain-deleted recombinant FVIII (BDD-rFVIII). While BDD-rFVIII is 
effectively used in the treatment of haemophilia A patients, recent experimental and clinical 
studies revealed a number of issues related to its equivalency to pd-FVIII (Gruppo et al., 
2003; Lollar 2003; Mikaelsson et al., 2001). In particular, it was shown that the activity of 
BDD-rFVIII determined by one-stage clotting assay is up to 50% lower than that determined 
by chromogenic assay, thus complicating determination of BDD-rFVIII activity in 
haemophilia A patient’s blood (Barrowcliffe et al., 2002). The meta-analysis of the data 
accumulated during long-term clinical usage of BDD-rFVIII revealed its lower efficiency in 
prophylaxis, giving a higher incidence of bleeding in comparison with full-length FVIII 
(Gruppo et al., 2003 and 2004). 
 
In this study, we evaluated the importance and the effect of the B domain region on FVIII 
expression and function by constructing factor VIII expression plasmids containing different 
lengths of the B domain. Those plasmids were expressed in mammalian cells and expression 
results were compared to the expression of a B-domain deleted factor VIII plasmid. For 
transient expression, three mammalian cell lines were transfected with the different 
constructs. For stable expression, we used CHO-DHFR[-] cell line. FVIII activity was 
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assessed in culture medium and FVIII antigen was assessed in culture medium and cellular 
lysates. FVIII proteins were purified from the produced cell lines that stably express FVIII. 
 
As the B domain comprises approximately 40% of the FVIII molecule and is located within 
the FVIII gene (exon 14), a complex cloning strategy was adopted in constructing those 
plasmids. The pMT2-FVIII vector containing the full length FVIII cDNA was used as a 
starting material. This vector contains a strong mammalian expression cassette and a gene for 
selection and amplification (DHFR). To construct the various expression plasmids, pMT2- 
FVIII was digested with RE to remove a large fragment within the FVIII cDNA representing 
part of the heavy chain, all the B domain and part of the light chain (from nt 1695 to nt 7302 
in the vector which corresponds to aa 195 to 2064 in the protein). The end of the B domain 
(aa 1634 to 1648) along with light chain part was then returned by a mutagenesis PCR to 
create the intermediate vector pMT2-FVIII-SNA. Fragments starting from position 1695 (aa 
195) and stopping at different serine positions in the B domain (aa 743, 844, 945, 1035 and 
1137) were then amplified by a mutagenesis PCR using the pMT2-FVIII as template and 
cloned into the intermediate vector pMT2-FVIII-SNA. With this cloning strategy we have 
successfully constructed the expression plasmids: pMT2-F8-BDD, pMT2-F8-101, pMT2-F8- 
202, pMT2-F8-292 and pMT2-F8-394 (see appendix). The correct cloning was then 
confirmed by restriction enzyme analysis and DNA sequencing (Fig. 17 and 18). 
 
To evaluate our tranfection method (Lipofection) and to select an optimal cell line to use for 
the functional studies, we have transiently expressed the different plasmids in three 
mammalian cell lines (HEK 293, COS-7 and CHO) and tested the level of FVIII expression in 
two medium collections. Our data show that lipofection is an efficient method of transfection 
as judged by the GFP expression of the pEGFP-C1 positive control plasmid that was 
transfected along with the different B-domain deleted expression plasmids in the three cell 
lines (Fig. 19). The CHO cell line, which has the shortest doubling time (24 hours) among the 
tested cell lines (DSMZ), showed the lowest FVIII expression level (as controlled by clotting 
assay FVIII: C). In both medium collections the average FVIII activity for the different 
constructs ranged from 1.67 % to 4.27 % in the first medium collection and from 2.5 % to 
7.27 % in the second medium collection. In contrast to the CHO cell line, HEK 293 and COS- 
7 cell lines showed a higher expression level in the first medium collection compared to the 
second collection, which meet the time required for their doubling (COS-7 doubles every 35- 
48 hours and HEK 293 doubles every 24-30 hours; DSMZ). In the first medium collection, 
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the average activity of the different constructs ranged from 8.4 % to 46.73 % in HEK 293 
cells and from 33.7 % to 56.33 % in COS-7 cells. In the second medium collection, the 
average activity of the different constructs ranged from 4.47 % to 24.4 % in HEK 293 cells 
and from 22.67 % to 44 % in COS-7 cells. Despite the fact that HEK 293 cells are of a human 
origin, our data showed a lower FVIII expression level in this cell line compared to COS-7 
cell line in both medium collections, which indicate that the FVIII B-domain variants 
expressed more efficiently in COS-7 cells. 
 
The COS-7 cell line, which showed the highest expression in terms of FVIII activity levels 
among the three cell lines, was then used for the functional studies on those constructs. The 
functionality was assessed by measuring the FVIII activity in culture medium using: (i) the 
clotting and the chromogenic assays, (ii) measuring the antigen level in culture medium and 
cellular lysates, (iii) calculating the specific activity and the total expressed protein of the 
different constructs, and (iv) comparing generally the expression of the constructs containing 
variable lengths of the B domain to the BDD construct. For this, COS-7 cells were transiently 
transfected with the different B-domain deleted constructs and the culture medium and 
cellular lysates was collected 48 hours after transfection. 
 
FVIII: C was determined in standard FVIII one-stage clotting and two-stage chromogenic 
assays, using a WHO FVIII standard as calibrator. The different constructs containing various 
lengths of the B domain showed close values between the two assay methods (Fig. 21) with 
the clotting assay showing slightly higher values, but there was no significant difference 
between the two assays values for each construct. This can be seen from figure 37, presenting 
the ratio between the FVIII: C values obtained in the one-stage clotting assay and the 
chromogenic assay. In each case it was 1.0 approximately. In contrast to this, the BDD 
construct showed higher FVIII activity value in the chromogenic assay in comparison to the 
clotting assay (fig. 21 and fig. 37). The difference between both results was significant as 
calculated by the student’s t-test (p < 0.05). This result confirms what was reported earlier in 
literature regarding the BDD-rFVIII (Barrowcliffe et al., 2002; Mikaelsson et al., 2001). 
From this data, we conclude that addition of even short parts of the B domain has a direct 
effect on FVIII physiology as such additions eliminate the assay discrepancy. This knowledge 
is important for the production of further recombinant FVIII concentrates, because until now, 
the difference of one-stage and chromogenic assays in determining the FVIII: C within 
patient’s plasma prevents a good, standardized clinical monitoring of hemophilia A patients 
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after substitution with BDD-FVIII. 
 
 
Figure 37: Ratio of the clotting assay activity value and chromogenic assay activity value for each of the 
different constructs containing various lengths of the B domain. 
 
 
The different constructs containing various lengths of the B domain showed higher clotting 
FVIII activity levels than the BDD construct (see fig. 21), ranging from slightly more than 
one fold to 2.5 folds as Figure 38 shows. The different constructs also showed a higher total 
expressed protein as measured by FVIII: Ag ELISA (see fig. 22) than the BDD construct, 
ranging from more than one fold to more than 2.5 folds (Fig. 39). Evaluating the functionality 
of the different constructs in terms of FVIII specific activity, our data show that the different 
constructs containing various lengths of the B domain show a higher specific activity than the 
BDD construct (Fig. 22). This high specific activity could also be seen within the medium of 
cells transfected with the 292 construct that has the lowest expression. This data indicate that 
the added lengths of the B domain improve the overall activity, protein synthesis and 
functionality of FVIII in comparison to the BDD-rFVIII. 
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Figure 38: The clotting FVIII activity in culture medium of the different constructs containing various lengths 
of the B domain given as multiple of the BDD construct activity. 
 
 
Figure 39: The total amount of expressed FVIII antigen (in culture medium and cellular lysates) of the different 
constructs containg various lengths of the B domain given as a multiple of the expressed BDD-FVIII construct. 
 
The increase in the secretion efficiency is attributed to not only the added length of the B- 
domain, but also to the added glycosylation sites (Fig. 16), which improves the protein 
trafficking through the secretory pathway. This data agrees with previous literature studied 
FVIII secretion (Miao et al., 2004; Pittman et al., 1993). 
 
The very low antigen secreted into the medium of the 292 construct (Fig. 21 B) but its high 
specific activity (Fig. 22 A) indicates that the FVIII product of this construct is functional but 
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poorly processed through the secretory pathway. This could be of a misfolded protein 
structure that will lead to degradation in the endoplasmic reticulum, but it has no influence on 
the functional activity of the small amount of secreted protein. 
 
The approximately similar activity and antigen values of the Bonn (in which the B-domain 
region is deleted between aa 852 and 1525, so this construct has ~113 aa of the amino 
terminal of the B domain and ~124 aa of the carboxy terminal of the B domain) and the 101 
construct (Fig. 21) indicates that the ~124 included amino acids from the B-domain end in the 
Bonn construct has no added effect on FVIII expression. This was expected as this part is 
naturally removed when FVIII undergoes intracellular proteolysis (Kaufman et al., 1988, van 
de Ven WJM et al., 1990, Hutton 1990, Barr 1991). FVIII is cleaved after residues 1313 and 
1648 within the B domain to generate a 200 kD heavy chain and an 80 kDa light chain (see 
fig. 4), giving rise to the heterodimeric molecule that circulates in plasma (Kaufman 1992). 
 
To have enough material for FVIII purification, the different recombinant FVIII constructs 
were stably expressed in CHO-DHFR[-]. In the CHO/DHFR expression system, the 
integrated gene of interest is expected to be coamplified with the DHFR gene by exposing 
rCHO cells to MTX. However, despite the stepwise selection, the foreign protein expression 
level of rCHO clones is not always increased with increasing concentrations of MTX (Kim et 
al., 2001). Clonal variation in regard to foreign protein expression naturally occurs probably 
because of different integration sites of the foreign gene as a result of unpredictable 
chromosomal rearrangement during gene amplification (Davies and Reff 2001; Flintoff et al., 
1984). CHO-DHFR[-] were transfected with the different constructs and cloning by limiting 
dilution method was performed twice, once after a round of selection of parental cell clones 
and once after obtaining high producer clones. We have successfully generated a high FVIII 
producing rCHO cell lines for the BDD (clone F2H1), the 202 (clone G3E6), the 394 (clone 
F4F3) and the Full length (clone C6) construct (see table 9). The different rCHO cell lines 
show different FVIII productivities and different growth rates that are slower than 
nonproducing clones. This data agrees with previous studies on producing recombinant clones 
in CHO cell line (Gu et al. 1994; Kim et al., 1998). 
 
Culture medium collected from the high producing rCHO cell lines was used for FVIII 
purification. FVIII was purified by a small-scale affinity purification method using FVIII-
Select beads. Purified materials were shown to be functional by the clotting FVIII: C assay 
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after diluting them in FVIII-deficient plasma (Table 10). After quantifying the purified 
material by FVIII ELISA (Table 11), equal antigen concentrations were used for thrombin 
cleavage. Comparing A2 cleavage patterns of BDD-rFVIII and 394-rFVIII, we could see that 
the BDD- rFVIII is more susceptible for thrombin activation showing a faster A2 generation 
pattern (Fig. 25). This result agrees with those of Eaton et al., 1986 where a B-domain deleted 
molecule was shown to exhibit increases sensitivity to thrombin activation compared with 
wild type and those of Meulin et al., 1988 where a B-domain deletion molecule was activated 
to a greater extent than wild type FVIII. However, our result disagrees with those of Pittman 
et al., 1993 in which no difference was detected in the rate of heavy chain cleavage of the 
BDD molecule and wild type FVIII by thrombin. In view of our result, we suppose that the B 
domain region has an important physiological role in FVIII activation. 
 
In conclusion, our data show that the addition of short lengths (~100-400 amino acids) of the 
B domain improved the overall expression of FVIII, eliminates the assay discrepancy and 
stabilizes the molecule upon activation. 
 
3.2 Construction of a new helper vector for the production of helper-dependent 
adenovectors for the use in hemophilia gene therapy 
 
Current treatment of hemophilia A consists of protein substitution therapies based on plasma- 
derived or recombinant FVIII. Although FVIII substitution therapy has significantly improved 
the quality of life of patients suffering from hemophilia A, it is not curative and a life-long 
dependency on clotting factor treatment is required (Ragni, 2004). Furthermore, the patients 
are still at risk of spontaneous bleeding episodes, which might cause significant morbidity and 
sometimes even mortality. Hence, it would be ideal if a cure for hemophilia A could be 
developed such that sustained therapeutic FVIII levels could be achieved. Hemophilia A is 
therefore considered to be a particularly attractive target disease for gene therapy. The 
molecular biology and pathology of this disease is relatively well understood and only a 
relatively slight increase in FVIII levels (above 1% of physiologic levels) suffices to convert a 
severe to a moderate hemophilic phenotype, which constitutes a major clinical improvement 
(Chuah et al., 2004). 
 
During the last few decades, a variety of different gene delivery technologies have been 
developed, each with their own advantages and limitations. Vectors derived from human 
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adenoviruses exhibit a number of features that have made them extremely useful gene transfer 
reagents. Most notably, these vectors can transduce a broad range of both dividing and post- 
mitotic cells of different origin. The ultimate form of adenovirus vector modification is the 
creation of fully deleted ‘helper-dependent’ adenovirus vectors (HD-AdVs). These are 
adenovirus-based vectors that contain only the cis elements necessary for replication and 
packaging, but lack all adenovirus genes. As they do not express any viral genes, they have a 
significantly improved safety profile compared with early-generation adenoviral vectors. HD- 
AdVs could give rise to prolonged transgene expression and were associated with 
significantly reduced acute and chronic hepatotoxicity and reduced inflammatory responses 
compared with first-generation adenoviral vectors, even in large animal models such as 
primates or dogs, which are more susceptible to the toxic side effects of adenoviral vectors 
than mice (Chuah et al., 2004). HD-AdVs created so far share a major disadvantage which is 
the use of helper viruses or plasmid cotransfection to provide the necessary virus proteins in 
trans. The use of helper viruses almost always results in some contamination of the vector by 
the helper virus. 
 
Recombinant baculoviruses are increasingly used as gene delivery vectors for mammalian 
cells (Kost et al., 2005). This relatively new gene delivery approach offers a number of 
advantages including the inability of the virus to replicate in mammalian cells, the absence or 
virtual absence of cytotoxicity, technical simplicity and superior biosafety profile as 
compared to mammalian cell-derived viral vectors (Kost et al., 2000). The demonstration that 
a recombinant baculovirus containing a 38 kb insert can be generated and propagated in a 
genetically stable manner in insect cells provides important direct evidence of the large 
cloning capacity of the virus (Cheshenko et al., 2001). 
 
In the present study, we have examined the potential utility of a novel helper system for the 
production of a HD-AdV carrying a B-domain-deleted factor VIII-cDNA without any risk of 
contamination. In this system, a packaging deficient, replication-competent adenovirus Helper 
construct was delivered by a baculovirus. This baculovirus / adenovirus hybrid genome was 
then delivered into HEK 293T cells along with the HD-AdV, where the adenoviral sequences 
integrated into the hybrid genome should provide (in trans) all of the functions necessary for 
the propagation of HD-AdVs. 
 
 
	   96	  
In designing our novel helper (the baculovirus / adenovirus hybrid) genome, we included only 
the Ad5 genes (nts 4000 to 35832) necessary for replication and packaging of HD-AdV. The 
adenoviral 5'ITR (nts 1-190), packaging signal (nts 191-358) and 3'ITR (nts 35833-35935) as 
well as E1/E3 region were deleted in this helper construct, thus rendering it replication 
incompetent and packaging incompetent. The replication capacity of the helper construct was 
then regained by fusing the Adeno-associated virus 2 (AAV2)-ITRs (5'ITR; 3'ITR) into it. 
AAV2-ITRs serves as origins of replication for the helper construct provided that AAV2- 
rep78/68 genes are provided in trans. (See also section 2.2.9 and 2.3.5) The helper construct 
(AAV2[5'ITR] /Ad5/ AAV2[3'ITR]) was then integrated into the Baculovirus genome 
generating the helper vector Bac-AAV2-Ad5. 
 
The cloning of such a big helper construct required a tedious lab effort. The big insert size (~ 
32 kb) with respect to the vector size (the Bac-shuttle plasmid of around 6 kb in size) required 
the screening of around 100 recombinant clones by size and restriction enzyme analysis. 
Doing this, we were able to isolate a clone, however with a small deletion within the 3'ITR 
region. This deletion was confirmed by Sma I restriction and DNA sequencing (Fig. 27 and 
28). After consultation with Prof. W Poller research group (our gene therapy collaborating 
group; Freie Universitaet Berlin), we continued work as this group assured that one ITR is 
enough to serve as an origin of replication. 
 
To guarantee the genetic stability of the helper construct in insect and mammalian cells and to 
prevent its self-circularization, we have provided the Rep genes in trans. in a separate 
baculoviral construct. The expression of the AAV2-Rep genes has been shown in SF9 and 
HEK 293 cells by RT-PCR (Fig. 29). The EGFP gene was cloned in a separate baculoviral 
construct and served as a positive control for HEK 293 cells infection (Fig. 35). 
 
Recombinant bacmids (bBac-AAV2-Ad5, bBac-AAV2-Rep and bBac-EGFP) were generated 
by site specific transposition with their corresponding shuttle plasmids and confirmed by Taq- 
PCR using M13 forward and reverse primers and insert specific primers (Fig. 30 and 31). 
 
For virus production, recombinant bacmids were used to rescue the recombinant Bac virus 
(vBac-AAV2-Ad5, vBac-AAV2-Rep and vBac-EGFP) in Sf9 insect cells. Viral titers of 5 * 
109 pfu/ml and 4 * 109 pfu/ml were achieved for vBac-AAV2-Ad5 and vBac-AAV2-Rep 
respectively and selected plaques were amplified. Viral DNA was extracted from purified 
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amplified viral stocks and tested by Taq-PCR to have the Ad5-chimera and the Rep genes. 
We have successfully isolated plaques (9 and 16) of vBac-AAV2-Ad5 and plaques (1 and 5) 
of vBac-AAV2-Rep that showed a genetic stability over passaging and found to have the 
correct inserts by Taq-PCR (Fig. 34). As the structure of the Ad5 insert in vBac-AAV2-Ad5 
did not change during passaging, this indicates that the presence of adenoviral sequences in 
the recombinant hybrid genome did not interfere with baculovirus growth. 
 
For the main experiment, the purified amplified Bac-AAV2-Ad5 helper virus (at MOI of 500 
and 2000) was used in combination with Bac-AAV2-Rep (at MOI of 200) to rescue the HD- 
AdV in HEK293 cells. As a positive control of transfection, one well was infected with pBac- 
EGFP. As a negative control of rescuing the HD-AdV, one well was infected with Bac- 
AAV2-Rep (at MOI of 500) only (no helper adenoviral construct). Assuming that inside the 
HEK 293 cells, the AAV2-ITR will function as an origin of replication and as a termination 
signal supported by the expression of the Rep78/68 protein and that the Ad5 helper construct 
in the hybrid genome will provide all Ad5 proteins necessary for replication and packaging of 
HD-AdV, the HD-AdV should be produced. This viral production should lead to lysis of 
HEK 293 as well as BDD-rFVIII should be expressed. 
 
Our results were not as expected as we have not seen any cytopathic effects after four days 
infection period. Nonetheless, to see whether the results were positive or no, medium was 
collected and HEK 293 cells were lysed. Lysates were partially used for extrachromsomal 
DNA extraction to control wether DNA of HD-AdV has been amplified in HEK 293 cells. 
Digestion with DpnI indicated that our isolated extrachromosomal DNA was not produced in 
vivo inside HEK 293 cells, but was of bacterial origin belonging to the transfected HD-AdV 
(Fig. 36). Culture medium was used for FVIII: Ag testing which was not detectable. A second 
portion of the lysates was used for a second round of infection (to amplify the helper 
dependent viral particles in case they were produced in a very low quantity) using fresh 
confluent HEK 293 cells in the presence of the same concentrations of the helper virus. Four 
days later, cells were lysed and lysates were used for a third round of HEK 293 infection. No 
signs of infection could be seen in the three rounds of infection. These results indicate that our 
helper system could not support the production of the helper dependent adenovector. 
 
Cheshenko et al., 2001 developed an alternative system for the propagation of HD-AdVs, in 
which the adenoviral genes (flanked by adenoviral ITRs) essential for replication and 
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packaging of the helper vector are delivered into producer cells by a similar baculovirus- 
adenovirus hybrid. This hybrid was constructed to carry a Cre recombinase-excisable copy of 
a packaging-deficient adenovirus genome. Their experiments resulted in a vector that was 
completely free of helper virus and was able to transduce cultured 293 cells. However, 
scaling-up of HD-AdV production was prevented by the eventual emergence of replication- 
competent adenovirus (RCA), apparently the product of homologous recombination between 
adenovirus sequences contained in 293 cells and the adenoviral helper genome (Kost and 
Condreay, 2002). The major difference between this system and the helper-dependent system 
is that, instead of deleting the packaging signal from the helper genome during the vector 
propagation, we have deleted it before it gets into cells. This modification precludes the 
packaging of this genome into adenovirus virions. Flanking the adenoviral genome by AAV2- 
ITRs instead of Ad5-ITRs will also prevent the appearance of RCA. 
 
In the design of this system we took advantage of a unique feature of the baculovirus 
AcMNPV to infect human cells efficiently while remaining virtually nontoxic and 
transcriptonally and replicatively inactive. The genome of AcMNPV consists of 131 kb 
double-stranded circular DNA molecule (Ayres et al., 1994). Although it was generally 
reported that the extra packaging capacity of baculovirus is high (Cheshenko et al., 2001), we 
could prove that the recombinant baculovirus Bac-AAV2-Ad5 created in this study was able 
to accomodate an insert of ~35824 bp, which apparently did not affect the virus viability. Our 
data suggest that, despite the presence of such a large insert, the genetic structure of Bac- 
AAV2-Ad5 remained stable, allowing passaging and expansion of the virus. In addition, we 
we were able to propagate those recombinant baculoviruses to relatively high titers (5 * 109 
pfu/ml) and further concentrate them by centrifugation, which agrees with Hofmann et al., 
1995. 
 
Since baculovirus genes are not expressed in mammalian cells, it is unlikely that the Bac/Ad5 
hybrid genome will replicate in mammalian cells. However, replication of adenovirus 
sequences in the helper hybrid genome is essential to generate the large number of templates 
for the synthesis of the large amounts of viral proteins that are necessary to obtain high yields 
of HD-AdV. Thus, in order to support the replication and packaging of the HD-AdV in an 
efficient fashion, the adenovirus helper genome should be able to replicate. To permit 
replication directed from the AAV2-ITRs flanking the Ad5 sequences, the AAV2-Rep genes 
were provided in trans in a separate baculovirus that was produced into high titers and 
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coinfected with Bac-AAV2-Ad5 helper hybrid. 
 
In conclusion, as the baculovirus was able to infect HEK 293 cells as shown by vBac-EGFP 
infection and the Rep genes are expressed in those cells, we propose that the HD-AdV was 
not produced because of inefficient or non occurring replication of the Ad5 genes in the 
Bac/Ad5 hybrid. The presence of only one ITR may be a possible cause that replication did 
not work (efficiently). Reconstructing such a helper hybrid to have both ITRs would validate 
our novel system and show its ability to support the HD-AdVs. 
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5. Summary: 
 
5.1 Functional studies on factor VIII protein variants containing different lengths of the 
B-domain 
 
To evaluate the role of the factor VIII (FVIII) B-domain on FVIII expression, (activity and 
activation), we constructed several FVIII expression constructs with various lengths of the B- 
domain and expressed them transiently as well as stably. 
 
Practically, B-domain deleted recombinant FVIII (BDD-rFVIII) was generated from the full- 
length FVIII-cDNA by ligating (on the protein level) Ser743 to Arg1634; the corresponding 
FVIII-cDNA was then cloned into the pMT2 expression vector. Then, cDNA-fragments of 
different length (on the protein level: 101, 202, 292, and 394 amino acid long fragments of the 
B-domain starting from its amino terminal) were cloned between Ser743 and Arg1634. 
Constructs were then transiently expressed in COS-7, HEK 293 and CHO cells and stably 
expressed in CHO-DHFR(-) cells by methotrexate selection and amplification. FVIII proteins 
were then assessed for activity in culture medium by the clotting assay and the chromogenic 
assay and for antigen in cellular lysates by ELISA. FVIII proteins were purified from stable 
cell lines media. 
 
Our transient expression studies showed that FVIII expression was the highest in COS-7 cells 
followed by HEK 293 cells. The CHO cells showed the lowest FVIII expression. Transient 
expression in COS-7 cells (for forty-eight hours) revealed that the constructs containing 
added lengths of the B-domain showed a higher FVIII: C (~1.1-2.5 folds) and a higher overall 
expressed protein (total antigen in medium and cellular lysates; ~1.1-3 folds) compared the 
BDD-rFVIII. The functionality of the expressed proteins in terms of FVIII specific activity 
was higher in all constructs in comparison to the BDD construct. Comparing the clotting 
FVIII activity by that of the chromogenic assay, we found that those constructs showed a 
slightly higher FVIII value within the clotting assay than within the chromogenic assay. In 
contrast, the BDD construct showed the opposite effect and also showed a significant 
discrepancy between both assay methods. Activation of purified FVIII proteins by thrombin 
revealed that the BDD-rFVIII showed a faster generation of the A2 domain than the 
constructs containing added lengths of the B-domain. 
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In conclusion, our data showed that the inclusion of a 100 amino acids or more of the B- 
domain sequence eliminates the assay discrepancy and increases the overall expression and 
functionality of rFVIII protein. 
 
5.2 Construction of a new helper vector for the production of helper-dependent 
adenovectors for the use in hemophilia gene therapy 
 
Fully deleted Helper-Dependent Adenovectors (HD-AdV) are so far the ultimate form of 
Adenovirus vector modifications which lack all the adenovirus genes except the replication 
and packaging elements. They can accommodate an insert of up to 36 kb. HD-AdVs are 
produced in HEK 293 cells in the presence of a helper adenovirus that supplies the viral genes 
in trans. Using this system very high titers of HD-AdV can be prepared now, with small but 
still measurable helper adenovirus contamination. 
 
Within this study we have tried to design a novel hybrid helper virus that can support the 
production of a HD-AdV, carrying a B-domain-deleted factor VIII-cDNA, in high efficiency 
without any contamination. In order to avoid contamination of HD-AdV production, the 
adenoviral sequences in the novel hybrid helper virus was lacking the adenoviral ITRs and the 
packaging signal, but was flanked by adeno-associated virus (AAV) ITRs. This adenoviral 
helper sequences was then cloned into the baculovirus expression system. 
 
The lack of the Adenovirus packaging signal renders the hybrid helper virus packaging 
incompetent and thus eliminates the risk of contaminating the HD-AdV preparations. Since 
the helper virus also lacks the adenoviral ITRs, it will not compete with the HD-AdV for the 
Adenovirus 5 replication proteins. The lack of the capsid genes within the AAV-sequences 
should also prevent the generation of AAV particles. 
 
To drive the replication of the Ad5-genome in the hybrid helper virus theAAV2-Rep genes 
were cloned in a separate baculoviral construct. A GFP baculoviral construct was prepared to 
be used as positive control for transfecting insect cells and infecting HEK 293 cells. 
 
We successfully constructed the hybrid helper vector pBac-AAV2-Ad5 with a deletion in the 
3’ITR region. The recombinant baculovirus particles (vBac-AAV2-Ad5, vBac-AAV2-Rep 
and vBac-EGFP) was then produced in insect cells, plaque purified and amplified to high 
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titers. Since the deletion within the 3’-ITR region should have no effect on helper virus 
production, the produced baculoviruses were used to infect HEK 293 cells, together with the 
HD-AdV carrying the B-domain-deleted factor VIII-cDNA. Depending on the presence of 
AAV-ITRs, we expected that the genome of the helper-virus will be replicated, thus 
improving its efficiency in providing helper function. To verify our strategy in synthesizing 
the helper virus, we showed that the baculovirus is able to infect HEK 293 cells by eGFP 
expression and that the Rep gene was expressed in both SF9 cells and HEK 293 cells. 
 
After three rounds of infecting HEK293 cells with the helper hybrid virus, we couldn’t see 
any signs of HD-AdV production. Unexpectedly, the analysis of extracted extra chromosomal 
DNA showed that the material was the original transfected material and not synthesized 
within the HEK 293 cells. 
 
In conclusion, as the baculovirus was able to infect HEK 293 cells and the Rep genes were 
also expressed in those cells, we propose that the HD-AdV was not produced because of 
inefficient or non occurring replication of the Ad5 genes in the Bac/Ad5 hybrid. The presence 
of only one ITR may be a possible cause. The reconstruction of an helper hybrid with both 
ITRs would clarify the function of such an adenoviral helper virus system. 
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7. Appendix 
 
Schematic representation of the newly constructed B-domain deleted expression vectors (pMT2-F8-BDD, 
pMT2-F8-101, pMT2-F8-202, pMT2-F8-292, pMT2-F8-394). 
 
 
 
 
 109 
7. Appendix 
 
 
 
 
 
 
Schematic representation of the newly constructed B-domain deleted expression vectors (pMT2-F8-BDD, 
pMT2-F8-101, pMT2-F8-202, pMT2-F8-292, pMT2-F8-394).  
 
 
 
